Development of Antimicrobial Agent with Novel Mechanisms of Actions and 1,2,4,5-Tetrazine Click Chemistry and its Application in DNA Postsynthetic Functionalization by Chen, Weixuan
Georgia State University
ScholarWorks @ Georgia State University
Chemistry Dissertations Department of Chemistry
Fall 12-7-2012
Development of Antimicrobial Agent with Novel
Mechanisms of Actions and 1,2,4,5-Tetrazine Click
Chemistry and its Application in DNA
Postsynthetic Functionalization
Weixuan Chen
Georgia State University
Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_diss
This Dissertation is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ Georgia State University. It has been
accepted for inclusion in Chemistry Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information,
please contact scholarworks@gsu.edu.
Recommended Citation
Chen, Weixuan, "Development of Antimicrobial Agent with Novel Mechanisms of Actions and 1,2,4,5-Tetrazine Click Chemistry and
its Application in DNA Postsynthetic Functionalization." Dissertation, Georgia State University, 2012.
https://scholarworks.gsu.edu/chemistry_diss/72
DEVELOPMENT OF ANTIMICROBIAL AGENT WITH NOVEL MECHANISMS OF ACTIONS  
AND 
 MECHANISTIC STUDIES OF 1,2,4,5-TETRAZINE CLICK CHEMISTRY AND ITS APPLICATION 
IN DNA POSTSYNTHETIC FUNCTIONALIZATION 
 
by 
 
WEIXUAN CHEN 
 
Under the Direction of Binghe Wang 
 
ABSTRACT 
SecA ATPase is a critical member of the Sec system, which is important in the translocation of 
membrane and secreted polypeptides/proteins in bacteria. Small molecule inhibitors can be very useful 
research tools as well as leads for future antimicrobial agent development. Based on previous virtual 
screening work, we optimized the structures of two hit compounds and obtained SecA ATPase inhibitors 
with IC50 in the single digit micromolar range. These represent the first low micromolar inhibitors of 
bacterial SecA and will be very useful for mechanistic studies.  
Post synthetic modification is an important and efficient way of DNA functionalization especially 
in DNA aptamer selection. In this research, the feasibility of norbornene (Neo) modified thymidine 
triphosphate incorporation was described. Besides, substituted tetrazines have been found to undergo 
facile inversed electron demand Diels-Alder reactions with “tunable” reaction rates. This finding paves 
the way to utilize tetrazine conjugation reactions for not only DNA but also other labeling work. 
 
INDEX WORDS: SecA inhibitors, Antimicrobials, Nature sources, Small molecule inhibitors, tetrazine, 
click chemistry, DNA post-synthetic functionalization  
DEVELOPMENT OF ANTIMICROBIAL AGENT WITH NOVEL MECHANISMS OF ACTIONS  
AND 
 MECHANISTIC STUDIES OF 1,2,4,5-TETRAZINE CLICK CHEMISTRY AND ITS APPLICATION 
IN DNA POSTSYNTHETIC FUNCTIONALIZATION 
 
 
 
 
by 
 
 
 
 
WEIXUAN CHEN 
 
 
 
 
 
 
 
A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
in the College of Arts and Sciences 
Georgia State University 
2012  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Weixuan Chen 
2012  
DEVELOPMENT OF ANTIMICROBIAL AGENT WITH NOVEL MECHANISMS OF ACTIONS  
AND 
 MECHANISTIC STUDIES OF 1,2,4,5-TETRAZINE CLICK CHEMISTRY AND ITS APPLICATION 
IN DNA POSTSYNTHETIC FUNCTIONALIZATION 
 
 
by 
 
 
WEIXUAN CHEN 
 
 
 
Committee Chair:  Binghe Wang 
 
Committee: Aimin Liu 
Suri S. Iyer 
 
 
Electronic Version Approved: 
 
 
Office of Graduate Studies 
College of Arts and Sciences 
Georgia State University 
December 2012 
iv 
 
DEDICATION 
I want to dedicate this dissertation to my parents (Guoquan Chen and Xiaoyan Ye). Without you, 
I would not be where I am today. You gave me spiritual as well as material support in my pursuit of 
knowledge. Your love and care cannot be compared by anything in the world.  
“You raise me up, so I can stand on mountains; 
You raise me up, to walk on stormy seas; 
I am strong, when I am on your shoulders; 
You raise me up to more than I can be.”-- Brendan Graham 
I also dedicate my work to my wife (Yanni Lin), your love, kindness, support, and 
encouragements have made everything possible.  
Finally, my grandfather (Huarong Chen), wish you could see my accomplishments and may you 
rest in peace. I love you forever. 
v 
 
 
ACKNOWLEDGEMENTS 
I owe my deepest gratitude to my advisor, Dr. Binghe Wang, whose encouragement, guidance 
and support enables me to be a chemist and a scientist. His personality and ways of doing things not only 
influent my research but most importantly teach me how to be a successful person. I would also like to 
thank Dr. Phang C. Tai, Dr. Aimin Liu, Dr. Suri S. Iyer, Dr. Donald Hamelberg and Dr. Zhen Huang. 
Their advices guide me throughout my PhD pursuing time. I want to show my great gratitude to all other 
faculty members and staffs for their help. 
 I am indebted to many of my colleges for their sensational supports and fruitful advices. 
Especially, I am grateful to Danzhu Wang for her generous help, to Dr. Chaofeng Dai for his direction 
and assistance in many ways, especially in the synthesis analysis, to Dr. Minyong Li for computational 
modeling, to Dr. Nanting Ni for all biological related work, to Dr. Lifang Wang for mass spectrometry 
work, and to Dr. Lupei Du, Dr. Shan Jin, Dr. Jianmei Cui, Dr. Guojing Sun, Dr. Bowen Ke, Dr. Yunfeng 
Cheng, Dr. Xiaochuan Yang, Dr. Krishna Damera, Dr. Suazette Reid, HanjingPeng, Sarah Burroughs, 
Alexander Draganov, Hang Tran, Ke Wang, Yueqin Zheng and all other group members for their 
discussions and helps in research. Financial support from the National Institutes of Health, the Molecular 
Basis of Disease program at GSU, the Georgia Cancer Coalition, and the Georgia Research Alliance is 
gratefully acknowledged. 
vi 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ....................................................................................................................... v 
LIST OF TABLES ................................................................................................................................... viii 
LIST OF SCHEMES ................................................................................................................................. ix 
LIST OF FIGURES .................................................................................................................................... x 
1 DEVELOPMENT OF ANTIMICROBIAL AGENT WITH NOVEL MECHANISMS OF 
ACTIONS ............................................................................................................................................. 1 
1.1 Introduction ................................................................................................................................. 1 
1.1.1 Urgent needs of antibiotics with unique mechanism of action ......................................... 1 
1.1.2 SecA as new target for antimicrobial agent design ........................................................... 3 
1.1.3 SecA inhibitors ................................................................................................................. 10 
1.1.4 Future directions .............................................................................................................. 16 
1.2 Results and Discussions ............................................................................................................. 17 
1.2.1 Chemistry .......................................................................................................................... 17 
1.2.2 Biological evaluation ........................................................................................................ 19 
1.2.3 Computational modeling .................................................................................................. 24 
1.3 Experimental part ..................................................................................................................... 25 
1.3.1 Chemistry .......................................................................................................................... 25 
1.3.2 Biological evaluation ........................................................................................................ 35 
1.3.3 Computational analysis .................................................................................................... 36 
1.4 Conclusion .................................................................................................................................. 37 
1.5 Acknowledgements .................................................................................................................... 37 
vii 
2 MECHANISTIC STUDIES OF 1,2,4,5-TETRAZINE CLICK CHEMISTRY AND ITS 
APPLICATION IN DNA POSTSYNTHETIC FUNCTIONALIZATION .................................. 38 
2.1 Introduction ............................................................................................................................... 38 
2.2 Results and discussions ............................................................................................................. 43 
2.2.1 Synthesis of Norbornene-modified deoxyuridine (Neo-TTP) ......................................... 43 
2.2.2 Enzymatic incorporation and post-synthesis labeling of Neo-TTP ................................ 44 
2.2.3 Development of new click reaction involving 1,2,4,5-tetrazine  and cyclooctynes ......... 45 
2.3 Conclusion .................................................................................................................................. 50 
2.4 Experimental part ..................................................................................................................... 50 
2.4.1 Synthesis ........................................................................................................................... 50 
2.4.2 Enzymatic incorporation and post-synthesis labeling ..................................................... 54 
2.4.3 Characterization of cyclization products ......................................................................... 55 
2.4.4 Kinetics measurements of 51, 55 and 56 with 50 or 53. .................................................. 57 
2.4.5 Computational detail ........................................................................................................ 60 
2.5 Acknowledgements .................................................................................................................... 61 
3 CONCLUSIONS ........................................................................................................................ 62 
REFERENCES .......................................................................................................................................... 63 
APPENDICES ........................................................................................................................................... 70 
Appendix A. 1H and 13C Spectra of compounds in chapter 1 ........................................................ 70 
Appendix B. 1H and 13C Spectra of compounds in chapter 2 ...................................................... 194
viii 
LIST OF TABLES 
Table 1.1. Major antibiotic classes by mechanism of action ........................................................................ 2 
Table 1.2. List of X-ray crystallography structures of SecA ........................................................................ 5 
Table 1.3. Fluorescein analogs RB and EB and their inhibitory properties ................................................ 15 
Table 2.1. Second order rate constants of cyclooctynes with tetrazines. .................................................... 47 
 
  
ix 
LIST OF SCHEMES 
Scheme 1.1. Synthesis of isoxazole carboxamides 21a-n. .......................................................................... 18 
Scheme 1.2. Synthesis of compounds 25a-g and 28a-i. ............................................................................. 19 
Scheme 1.3. Synthesis of compounds 29a-g, 30a-i and 31d,e,g-i. ............................................................. 19 
Scheme 2.1. Illustration of boronic acid-diol interaction ............................................................................ 39 
Scheme 2.2. Solid-phase synthesis of boronic acid modified DNA through copper-free post-synthesis 
modification ................................................................................................................................................ 41 
Scheme 2.3. Synthetic route of Neo-TTP 48 .............................................................................................. 43 
Scheme 2.4. Reagents and conditions for the synthesis of cyclooctyne 50 ................................................ 51 
Scheme 2.5. Reagents and conditions for the synthesis of (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethanol 
(endo-53) ..................................................................................................................................................... 51 
Scheme 2.6. Reagents and conditions for the synthesis of 3,6-diphenyl-1,2,4,5-tetrazine 51. ................... 52 
Scheme 2.7. Reagents and conditions for synthesis of 3,6-di(pyridin-2-yl)-1,2,4,5-tetrazine 55 ............... 52 
Scheme 2.8. Reagents and conditions for the synthesis of N-isopropyl-4-(6-(pyrimidin-2-yl)-1,2,4,5-
tetrazin-3-yl)benzamide 56 ......................................................................................................................... 53 
 
 
  
x 
LIST OF FIGURES 
Figure 1.1. A schematic model of the preprotein secretion pathway in bacteria. ......................................... 5 
Figure 1.2. Space filling models of SecA dimers.......................................................................................... 6 
Figure 1.3. Three-dimensional structure of the E. coli SecA monomer. ....................................................... 7 
Figure 1.4. Two separable soluble domains and lipid-specific domain of SecA. ....................................... 10 
Figure 1.5. Structures of SecA Inhibitors found in nature and their natural analogs .................................. 12 
Figure 1.6. Reported SecA inhibitors.......................................................................................................... 13 
Figure 1.7. Structure optimization of SecA inhibitors (hit) by the Wang/Tai Labs .................................... 15 
Figure 1.8. Hit compounds and their derivatives ........................................................................................ 17 
Figure 1.9. Inhibitory effect of compounds 8 and 21a-n at 100 μM against EcN68 Sec A. ....................... 20 
Figure 1.10. Inhibitory effect of compounds 30a-i at 30 μM against EcN68 Sec A. ................................. 21 
Figure 1.11. Inhibitory effect of compounds 30c-e, g-i at 5 μM against EcN68 Sec A. ............................. 21 
Figure 1.12. Inhibitory effect of compounds 31d, e, g-i at 30 μM against EcN68 Sec A. ......................... 22 
Figure 1.13. The inhibitory curves of the two most potent compounds, 30g and 30h, against EcN68 Sec A.
 .................................................................................................................................................................... 22 
Figure 1.14. The inhibitory curves of 30g,h and 31h against EcSecA. ...................................................... 23 
Figure 1.15. The inhibitory curves of 30g,h and 31h against bacterial growth. ......................................... 24 
Figure 1.16. (A) The proposed docking conformation of HTS-12302 (white sticks) and compound 30g 
(green sticks) around SecA ATP-site; (B) The proposed schematic interactions of HTS-12302 with SecA; 
(C) The proposed schematic interactions of compound 30g with SecA ..................................................... 25 
Figure 2.1. Incorporation of boronic acid moiety into DNA through pre-installed B-TTP ........................ 40 
Figure 2.2. Illustration of Solid-phase synthesis of modified DNA through copper-free post-synthesis 
modification involving inverse-electron demand Diels-Alder reaction ...................................................... 42 
Figure 2.3. Enzymatic incorporation and post-synthesis labeling of Neo-TTP 48 with 49 ........................ 44 
xi 
Figure 2.4. Primer extension using Neo-TTP catalyzed by Klenow fragment (3’-5’exo-) and post-
synthetic modification using “click” reagent 49, 20% PAGE analysis ....................................................... 45 
Figure 2.5 Strain-promoted [4+2] cycloadditions of 1,2,4,5-tetrazine 51 and cyclooctynes 53. ................ 46 
Figure 2.6. Orbital energy of cyclooctynes and tetrazines .......................................................................... 47 
Figure 2.7. Schematic representations (energy vs. reaction coordinate) of the reaction between diphenyl 
tetrazine and strained alkynes. .................................................................................................................... 49 
Figure 2.8. Reaction rate between Ph-tetrazine 51(25 uM) and alkyne 50(450 uM). ................................. 57 
Figure 2.9. Reaction rate between Py-tetrazine 55(25 uM) and alkyne 50(250 uM, 300 uM, 350 uM, 400 
uM, 450 uM). .............................................................................................................................................. 58 
Figure 2.10. Reaction rate between Ph-tetrazine 51(25 uM) and alkyne 53(250 uM, 300 uM, 350 uM, 400 
uM, 450 uM). .............................................................................................................................................. 59 
Figure 2.11. Reaction rate between Py-tetrazine 55(25 uM) and alkyne 53(250 uM, 300 uM, 350 uM, 400 
uM, 450 uM). .............................................................................................................................................. 59 
Figure 2.12. Reaction rate between IsoP-tetrazine 56(25 uM) and alkyne 53(250 uM, 300 uM, 350 uM, 
400 uM, 450 uM). ....................................................................................................................................... 60 
 
1 
1 DEVELOPMENT OF ANTIMICROBIAL AGENT WITH NOVEL MECHANISMS OF 
ACTIONS 
Abstract: This chapter is mainly based on my publications: Bioorg. Med. Chem. in 2010, from page 1617-
1625. SecA ATPase is a critical member of the Sec system, which is important in the translocation of 
membrane and secreted polypeptides/proteins in bacteria. Small molecule inhibitors can be very useful 
research tools as well as leads for future antimicrobial agent development. Based on previous virtual 
screening work, we optimized the structures of two hit compounds and obtained SecA ATPase inhibitors 
with IC50 in the single digit micromolar range. These represent the first low micromolar inhibitors of 
bacterial SecA and will be very useful for mechanistic studies. 
1.1 Introduction 
1.1.1 Urgent needs of antibiotics with unique mechanism of action  
In the history of drug discovery, one can say with a high degree of confidence that no other field 
has experienced the wide swing of interest and perceived human needs than the field of antimicrobial 
development. Before antibiotics became widely available in the 1940’s, simple infections routinely led to 
death. Therefore, interests in new antibiotics were very high at that time and needs were real. However, 
with the advent of a large number of modern antibiotics in different classes with various mechanisms of 
action, it was perceived by many that no major effort would be needed to develop new antibiotics because 
cure could be achieved in essentially all cases of bacterial infection with some rare exceptions, which 
often were complicated by other factors. However, this thinking has changed in the last decade because of 
the wide-spread emergence of drug resistant bacterial strains. For example, methicillin-resistant 
Staphylococcus aureus (MRSA) has become a major issue in hospital-related infections. It has been 
reported that each year there are more deaths caused by MRSA than by HIV and deaths caused by 
hospital-acquired infection alone stand at about 90,000 per year in the US.1 It is expected that bacterial 
infection will once again become a major disease killing a large number of people if no new 
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antimicrobials are developed. Despite the realization of the urgent human need for new antimicrobials, 
research in this direction has been lagging for one simple financial reason.2 Any new antimicrobials 
effective against drug resistant strains will not be used as the first line of treatment options (for good 
reasons).  This means that there is not much money to be made. Therefore, pharmaceutical industry is 
essentially staying away or at least not focusing on new antimicrobials. This makes it even more 
important that academic labs and other non-profit institutes recognize this long-term need and devote 
adequate effort to the development of new antimicrobials. Along this line, it is especially important that 
efforts be focused on developing new therapeutic options that have novel mechanisms of actions and can 
overcome current drug resistant problems. To help put this review in a historical perspective, Table 1.1 
lists major families of antibiotics with their mechanism of actions.3   
Table 1.1. Major antibiotic classes by mechanism of action 
Mechanism of action Antibiotic families Representative Structures 
Inhibition of cell 
wall synthesis 
Beta-lactams (penicillins, 
cephalosporins, 
carbapenems, 
monobactams); 
glycopeptides (vancomycin, 
teicoplanin); 
cyclic lipopeptides 
(daptomycin) 
 
penicillin 
 
glycopeptide 
Inhibition of protein 
synthesis 
Tetracyclines; 
aminoglycosides; 
oxazolidonones (linezolid); 
streptogramins 
(quinupristin-dalfopristin); 
ketolides; 
macrolides; lincosamides, 
 
Tetracycline 
 
Inhibition of DNA 
synthesis Fluoroquinolones 
 
Fluoroquinolones 
Inhibition of RNA 
synthesis Rifampin 
 
Rifampin 
3 
Inhibition of folic 
acid synthesis Sulfonamides; trimethoprim  
Sulfonamides 
Membrane 
disorganizing agents 
Polymyxins (polymyxin-B, 
colistin) 
 
Other mechanisms Metronidazole 
 
Metronidazole 
 
1.1.2 SecA as new target for antimicrobial agent design 
In selecting a new target, the following characteristics are strongly desirable. First, the target 
plays an essential function in bacterial survival and there is no alternative pathway for mitigation and 
compensation. This also offers the possibility of developing broad-spectrum antimicrobials. Second, there 
is no closely related human homolog to minimize the issue of potential toxicity. Third, the target also 
contributes to bacterial virulence and lethality. With these factors in mind, we are interested in developing 
inhibitors of bacterial protein secretion with the specific target being SecA (Fig. 1), which is an 
indispensable ATPase of the protein translocation machinery present in all bacteria, is critical for bacterial 
survival, and is responsible for the secretion of many essential proteins as well as some toxins and 
additional virulence factors.4-7 All these characteristics make SecA an ideal target for antimicrobial 
development. Below we discuss in detail this target, the current state of research, and future directions. 
1.1.2.1 SecA is an ATPase 
It is said that in any given organism, membrane and secreted polypeptides/proteins comprise 
more than 30% of the proteome; and no less than 10% of proteins cross a membrane before arriving at 
their final locations of function.8,9 In bacteria, more than 30% of the proteins are located in or outside the 
4 
cellular cytoplasmic membrane. Several protein transport mechanisms exist in bacteria to allow for the 
needed transport and translocation.10 The Sec-dependent protein translocase consists of oligomer complex 
of SecYEG and SecDF as membrane proteins11,12 and SecA functions as an ATPase that provides the 
energy for the Sec-dependent protein translocation. When SecA is bound to the SecYEG complex, acidic 
phospholipids and a precursor protein such as proOmpA (the precursor of outer membrane protein A), it 
becomes fully active as an ATPase and a protein translocase.13,14 Details of the SecA-mediated secretion 
process have been discussed elsewhere.15-17 Briefly, the transport process has the following events (Fig. 
1.1): (1) SecB binds the preprotein and then SecA;18,19 (2) the pre-protein bound SecA sees and binds to 
the lateral gate SecY20 of the SecYEG hetero-trimeric complex; (3) electrostatic gate opening21 occurs due 
to allosteric regulation; (4) ADP is released from the SecA motor domains19,21,22 and SecA C-terminal 
domain mediated suppression relieves; (5) SecA acquires the translocation ATPase activity,14,23 and (6) 
SecYEG channel  loosens24 and gets ready for pre-protein to be pushed in by the intramolecular regulator 
of ATPase activity 1 domain (IRA1) helix-loop-helix element in SecA. As the final step of the secretion, 
the signal peptide is cleaved by signal peptidase leading to the release of the mature protein, which gets 
folded later. As a major component of the bacterial Sec-system, domain organization of SecA was 
revealed by crystallographic structures from different species25-30 and by biochemical analyses.31-35 
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Figure 1.1. A schematic model of the preprotein secretion pathway in bacteria. Modified from Segers et al 
Chemistry & Biology, 2011, 18, 685-698 with permission from (2011) Elsevier36 
SecA structures have been studied using X-ray crystallography (Table 1.2) and NMR 
spectroscopy18, cryo-EM,37-39 atomic force microscopy,37 small angle X-ray scattering40 and small angle 
neutron scattering (SANS).41 Most of these studies revealed a dimeric structure for Sec A with one 
exception.26 Interestingly, in each of the SecA structures, the protomer structures are very similar. 
However, the orientation of each protomer relative to one another is quite different in every dimeric 
structure. In most dimers, their C-domains face opposite directions creating anti-parallel structures (Fig. 
1.2 A), while one has a parallel orientation (Fig. 1.2 B). 
Table 1.2. List of X-ray crystallography structures of SecA 
Organism 
PDB 
entry 
Ligand Additional structures 
M. 
tuberculosis 
1NL329  1NKT (ADP, Mg2+) 
B. subtilis 2IBM27 ADP  
T. 
thermophiles 
2IPC30   
E. coli 2FSF15  
2FSG (ATP), 2FSH (AMP-PNP), 
2FSI (ADP) 
B. subtilis 1M6N25  1M74 (ADP, Mg2+,SO42- ) 
B. subtilis 3JV242 ADP, Mg2+, peptide  
B. subtilis 3DL843   
B. subtilis 1TF520  1TF2 (ADP, Mg2+) 
T. maritima 3JUX42 ADP, Mg2+  
T. maritima 3DIN43 ADP, Mg2+, BEF  
E. coli 3BXZ44 
ADP, Mg2+, 
spermidine 
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Figure 1.2. Space filling models of SecA dimers.  
Dimeric SecA proteins were structurally aligned on one of their protomers (the nucleotide binding domain NBD, red; the intramolecular regulator 
of ATPase 2 IRA2, dark blue; the protein binding domain PBD, yellow and the C-domain, purple) so as to demonstrate the variable position that 
the second (grey) protomer occupies; arrows indicate C terminus. The figure was created using the UCSF Chimera package.4546 The structures 
used are: Escherichia coli (ecSecA 1;2FSF).28 Thermus thermophilus (ttSecA; 2IPC).30 Bottom: Residue boundaries of SecA domains of different 
organisms 
Each SecA protomer contains several sub-structural domains (Fig. 1.2). The nucleotide binding 
domain (NBD) and the intramolecular regulator of ATPase activity 2 domain (IRA2) forms the “DEAD” 
motor, the main catalytic moiety of SecA. The ATP binding site of SecA is located at the interface of the 
NBD and the IRA2 domains. SecA is a member of the superfamily II (SF2) DExH/D proteins, the 
majority of which are helicases.47,48 Other than helicases, to achieve the unique functions of SecA, the 
preprotein binding domain (PBD) and the C-terminal domain are two key domains that contribute to 
SecA substrate specificity. The PBD is composed of two sub-domains: an antiparallel β strand (stem) 
connects PBD and NBD, and a bilobate globular domain (bulb).33,49 The C-terminal domain is composed 
of four substructures: the wing domain (WD), the α-helical scaffold domain (SD), the intramolecular 
regulator of ATP activity 1 domain (IRA1), and a C-terminal linker (CTL). 
ttSecA 1 ecSecA 1A  B 
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Figure 1.3. Three-dimensional structure of the E. coli SecA monomer.  
Color coding of SecA domains: NBD, red; IRA2, dark blue; SD, cyan; HWD, orange; PBD, yellow; IRA1, purple; and CTL (first 4 residues), 
black. The bound ATP molecule is shown in ball and stick (colored by elements). The figure was created using the UCSF Chimera package, 
using the coordinates of the EcSecA (PDB code 2FSG).28 
1.1.2.2 The ATPase activity of SecA is regulated by the NBD and the IRA2 domains 
The opening and closing of the nucleotide-binding cleft, which is located in the gap between the 
NBD and IRA2 domains, play the key role in SecATPase activity regulation.14,34,50,51 The complex 
conformational changes upon binding the DEAD motor and C-terminal domain of SecA to SecYEG 
complex control the interactions between NBD and IRA2. Before binding to SecYEG, cytoplasmic SecA 
has high affinity for ADP. Therefore this ADP-bound SecA shows low intrinsic ATPase activity and low 
affinity for the SecYEG complex.22,25 Binding with SecYEG in the membrane weakens the interactions 
between the NBD and IRA2 domains and stimulates the ATPase activity. The SecA with elevated 
ATPase activity is named “membrane ATPase.” Besides, binding of the DEAD motor and C-terminal 
domain of SecA to the SecYEG complex triggers conformational changes at the interface among the 
IRA1, PBD, and CTL domains. These allosteric changes increase the SecA affinity for signal peptides as 
well. Consequently, binding of the signal peptide near the stem region of the PBD-NBD interface causes a 
large rotation of the bulb domain, which drives trapping of the first amino-terminal segment of mature 
W775 
ATP 
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pre-protein domains.19,31,42 This binding further increases the ATPase activity of SecA and converts it into 
a translocation ATPase. At this stage, the C-terminal domain inhibition effect is totally relieved and the 
Gate 1 salt bridge is open at the base of the DEAD motor.21 Next, the DEAD motor ADP affinity is lost 
while the IRA2 detaches from the NBD and becomes disordered.21,52 ADP released from the DEAD 
motor induces the PBD (with the trapped preprotein) conformational changes33,52,53 and the dissociation of 
SecB.54 Later ATP binds to the empty nucleotide-binding cleft, brings subsequent conformational changes 
that causes insertion of SecA along with bound pre-protein into the SecYEG channel. Finally, ATP 
hydrolysis drives a small segment of the pre-protein release from SecA into the SecYEG channel.20 The 
SecA returns to the NBD-IRA2 tight interaction state that forces SecA to exit the SecYEG channel while 
the PBD moves further along the pre-protein chain55,56 and re-attaches onto the following pre-protein 
segment, which causes ADP release and allows a new round of ATP binding and hydrolysis.57  In order 
for the whole pre-protein to cross the channel, the co-insertion of pre-protein through the channel in 
segments is approximately 30 residues at a time.58,59 
1.1.2.3 Established methods to test inhibitory effects on the functions of SecA 
Given the essential role that SecA plays, it is easy to understand that this can be an attractive 
target for the development of broad-spectrum antibacterial agents with a novel mechanism of action. 
However, effort in developing inhibitors for SecA has been lacking. One reason could be the complexity 
and difficulties in assaying compounds for inhibitory activities. An added question is how the enzyme 
assay results would correlate with what is relevant in whole bacteria. 
A number of SecA assays are available including ATPase activity assay, protein translocation 
assay, an electrophysiology assay, and of course ultimately whole cell assay.60 All ATPase assays rely on 
the determination of free inorganic phosphate formed as a result of ATP hydrolysis. In the doing so, the 
malachite green colorimetric method is most commonly used.61-63 
In screening for potential inhibitors, the most obvious one is the use of the whole SecA in 
determining how an inhibitor modifies the ATPase activity. However, whole SecA is in a regulated, 
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closed-state largely controlled by its regulatory C-terminal (C34) domain. Therefore this is a minimally 
active state of SecA. Thus results generated using the whole SecA do not truly reflect the ability for the 
inhibitor to inhibit the fully active ATPase, which is the case when SecA is in membrane. Another assay 
method uses truncated SecA with only the catalytic domain (N68) in solution (e.g., EcSecA-N68, 
unregulated ATPase Fig. 1.4). Because of the lack of the inhibitory C-terminal domain, this assay is very 
sensitive. It has also been demonstrated that results from assays using the truncated form parallels that of 
the in vivo and membrane SecA assays.60 Another way of avoiding the intrinsic inhibition effect of the C-
terminal domain is by using a mutant with elevated intrinsic activities. For example, in EcSecA residue 
W775 is important for the C34 regulation,64 which is located at the interface of the SD and the IRA1 
domains (Fig. 1.3). Replacing the bulky tryptophan with a small hydrophobic alanine weakens the 
interaction of the SD and the IRA1 domains and elevates the intrinsic ATPase activity by 5-fold 
compared to the wild-type EcSecA.52,64 Therefore, using this mutated W775A EcSecA allows the benefit 
of the full-length enzyme without the intrinsic inhibition effect of the C-terminal domain.17 
Because the functional form of SecA as a motor exists in the membrane alone (membrane 
ATPase) or in complexation with SecYEG (translocation ATPase), these two forms can also be use is 
inhibitor screening.14,65 The only thing is that experimentally they are more cumbersome than the 
solution-phase enzyme assays described above. For functional assays, in vitro translocation of proOmpA 
into membrane vesicles (protein translocation assay) developed by the Tai lab is commonly used.66,67 As 
an easy demonstration that SecA alone can form protein-conducting channel,68 assay for SecA activities 
in liposome was also developed. Therefore, an array of in vitro assays is available for examining the SecA 
ATPase activity and protein translocation ability and for cross-validating results. 
As with any assay, truly mimicking the physiological conditions is a critical issue. This is 
especially true when it involves a membrane protein. Along this line, a semi-physiological assay for 
electrophysiological measurement of protein-channel activity in the oocytes was developed by the Tai 
lab.68,69 This assay is useful because of the ease of use, the small amount of materials (nanograms) needed, 
and the ability to study individual oocytes. The large size of oocytes can easily accommodate various 
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manipulations and electrode penetration and the recording noise is very low due to the large number of 
channels measured in such experiments (calculated to be 200-1,000,000 channels).69 The activity is 
strictly dependent on the injection of exogenous SecA and membrane vesicles. Results from this assay 
parallels that of antimicrobial assays very well, further supporting the near physiological nature of this 
assay system. 
It is important to emphasize that because of the membrane environment needed for SecA function 
as a transporter, inhibition studies need to involve different assay techniques in order to achieve a 
thorough understanding of the ability for these inhibitors to inhibit SecA functions. It is also possible that 
different inhibitors may exhibit varying affinities for the different forms of SecA. However, the results 
from the truncated SecA assay and the electrophysiology oocyte assays seem to parallel that of 
antimicrobial results. One of our recent publications has a detailed discussion of this aspect.60 
 
Figure 1.4. Two separable soluble domains and lipid-specific domain of SecA.  
There exist two forms of SecA in the membrane: SecAS, which is similar to the soluble form with 2 separable domains: N68 and C34, and the 
other SecAM with the N36 and M48 domains spanning the lipid membrane.70 Top: X-ray ribbon structure of EcSecA with N68 (Yellow) and C34 
(Green).  
1.1.3 SecA inhibitors 
So far, only a limited number of SecA inhibitors have been reported.17 Some are isolated from 
natural sources (such as fungi and plant) and others are synthetic. The oldest known inhibitor of SecA is 
N68 C34                     609
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the inorganic azide, which was first reported in 189171 to possess antimicrobial activity. Later on72 the 
antimicrobial activity was attributed to its ability to inhibit SecA mediated protein translocation. However, 
azide also inhibits many other enzymes such as cytochrome c oxidase,73,74 superoxide dismutase,75 alcohol 
dehydrogenase,76 and ceruloplasmin.77 Therefore, it is hard to imagine how azide can be used as an 
antimicrobial for in vivo applications. 
1.1.3.1 SecA inhibitors from natural sources 
Two natural products (1 and 2, Fig. 1.5) have been reported to possess modest antibacterial activities 
by inhibiting SecA. Compound 1(CJ-21058), isolated from an unidentified fungus (CL47745) broth, 
showed an IC50 of 15μg/ml against SecA and an MIC of 5μg/ml against multi-drug resistant S. aureus and 
Enterococcus faecalis.78 Interestingly, CJ-21058 was found to be a close analog of Equisetin, a fungal 
toxin from white mold Fusariumequiseti, previously isolated by the same group. Equisetin differs only in 
having a hydrogen atom at C-4 position of CJ-21058. It is also known to show a broad range of biological 
activities such as antibacterial, anti-HIV, cytotoxicity and DNA binding properties.79 The SecA inhibition 
activity of CJ-21058 was evaluated using malachite green assay for monitoring ATP hydrolysis using the 
SecA mediated translocation of proOmpA through the inner membrane vesicles bearing the heterotrimeric 
SecYEG complex. The striking structural similarities between CJ-21058 and Equisetin as well as their 
potent antibacterial properties point towards a possible correlation between antibacterial and SecA 
inhibitory activities of these compounds. A comparison of the common structural features between the 
two compounds clearly indicates that the methyl group at C-4 position (in CJ-21058) of hydrophobic 
bicyclic moiety seems to be contributing to the enhancement of antibacterial activity. 
Another report of a natural SecA inhibitor came from antisense-based random screening of nearly 
115,000 compounds against a sensitized strain of S. aureus having an inducible SecA antisense construct. 
The strategy behind the antisense-based screening involves selectively expressing an antisense RNA, 
which can bind to the mRNA of the targeted gene, causing its degradation. This results in decreased 
translation, leading to lesser gene product formation and causing subsequent sensitization of the 
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weakened strains to the inhibitors of the gene product. A two-plate agar-based differential sensitivity as-
assay was used to selectively screen compounds that target SecA, by comparison of growth inhibition of 
sensitized SecA antisense strain against wild-type control strain of S. aureus. A similar strategy was also 
used to establish that SecA is essential for S. aureus viability.80 Using this methodology, a cis-decalin 
secondary metabolite, pannomycin (2), extracted from a leaf litter fungus Geomyces Pannorum, was 
found to possess weak antibacterial activity against Gram-positive bacteria B. subtilis (MIC, 0.4 mM), S. 
aureus (MIC, 1.4 mM) and E. faecalis (MIC, 1.4mM)81. Interestingly, a structural analogue of 
pannomycin named cissetin also contains a tetramic acid moiety (similar to CJ-21058) and shows a MIC 
of 10 µM against MRSA strains82. From a structural comparison of common features essential for activity 
amongst the natural SecA inhibitors (CJ-21058 and pannomycin), the authors speculated that the 
hydrophobic decalin core with a quaternary carbon atom and the tetramic acid moiety seem to be the 
minimum structure requirement for SecA inhibition. Although, the inhibitory potential of these natural 
compounds is only modest, they offer a promising starting point for structure optimization. 
 
Figure 1.5. Structures of SecA Inhibitors found in nature and their natural analogs 
1.1.3.2 Synthetic small-molecule inhibitors 
In the field of drug discovery, a common approach to finding new chemical scaffolds active 
against a target of interest is computer based virtual screening (VS). The method includes both ligand-
based and structure-based. There have been some efforts towards high throughput random screening and 
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structure-based virtual screening of chemical libraries to obtain new scaffolds for SecA inhibition. Re-
Researchers at Wyeth-Ayerst83 carried a random screening of compound libraries using cell-based assays. 
The idea was to employ a SecA-lacZ reporter fusion to identify compounds that enhance SecA expression 
through inhibition of protein secretion. SecA is known to autogenously regulate its expression under 
normal protein secretion, by binding to its own mRNA, blocking the translation active site and inhibiting 
its expression. In contrast, inhibition of secretion dissociates the SecA-mRNA complex and causes an up-
regulation of SecA. With this approach, both synthetic and natural product libraries were screened for 
compounds that enhance SecA expression. A set of diverse structures showing modest antibacterial 
activities was obtained. For example, compound 5 showed a MIC50 value of 2µg/ml for S. aureus RN 
8081. Compounds 5 and 7 (Fig. 1.6) share some common structural motifs such as the presence of an 
imino moiety and lipophilic characteristics. However, these compounds were also associated with high 
cell toxicity (>75% growth inhibition at 10μg/ml) due to membrane damage. The compounds reported 
induce the overexpression of SecA and function by inhibition of protein secretion, but their SecA 
inhibition activity was not tested. Thus it is not certain whether the mechanism of action is through SecA 
inhibition. No further efforts have been reported to explore their potential as SecA inhibitors possibly due 
to the associated high toxicity. 
 
Figure 1.6. Reported SecA inhibitors 5, 683 and 784 
A series of thiazolo[4,5-d]pyrimidine derivatives84 were recently reported to inhibit Sec A. The 
compounds were obtained by using an in vitro malachite green screening method employing recombinant 
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E. coli or S. aureus SecA. The compounds were also tested for inhibition of protein translocation using 
membrane vesicles containing overexpressed SecYEG and the E. coli preprotein AlkProPhoA(Cys-).17 
The most potent compound 6 (Fig. 1.6) exhibited mixed-type inhibition with a high IC50 value of 135 µM 
against EcSecA intrinsic ATPase and also showed minor effects on the translocation ATPase activity of 
SecA with IC50 nearly 200 µM. Although, the compounds synthesized showed weak SecA and protein 
translocation inhibition, the thiazolo[4, 5-d] pyrimidine scaffold introduced by this report has the potential 
for further optimization to achieve high potency. 
The Wang and Tai labs undertook the first rational approach towards discovering new SecA 
inhibitors based upon in silico screening of small molecule ligand libraries.85  Virtual screening of a 
library of nearly 115,000 compounds was conducted using structure-based methods against the E. coli 
SecA active site. Nearly 30 top ranked compounds were tested in vitro for inhibition of ATPase activity 
against E. coli N68. Two modest inhibitors were obtained (Figure 1.7, 8 and 9) showing IC50 values 
around 100 µM. To obtain a sense of binding patterns and to aid in further structure optimization for 
analog synthesis, molecular docking of compounds 8 and 9 in the active site of E. coli SecA was 
conducted. The two modestly active compounds showed different structural features and somewhat varied 
binding orientations, which suggested that there is much room for structural optimization in order to 
further improve potency. Further optimization of the isoxazolecarboxamide series (8) was carried out with 
the focus being on the aryl group attached to the amide. In the second series (9), we started by testing 
different aryl structures flanking the central ring followed by 5-cyano-6-aryl-2-thiouracils derivatives. A 
further simplified ‘monomer” series of compounds was also prepared to understand the core structural 
need for inhibition. The compounds were tested in vitro using EcN68 SecA and the whole EcSecA. In 
vivo studies were done with a leaky mutant NR698 and wild type E. coli strain MC4100. 
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Figure 1.7. Structure optimization of SecA inhibitors (hit) by the Wang/Tai Labs 
In a recent development, several fluorescein analogs were tested against E. coli and B. Subtilis SecA. 
Two analogs Rose Bengal (RB) and erythrosine B (EB) were found to show strong inhibition on all three 
forms of SecA, SecA mediated protein translocation and antimicrobial activity (Table 1.3).60  
Table 1.3. Fluorescein analogs RB and EB and their inhibitory properties 
 RB EB 
In vitro 
(IC50/μM) 
Unregulated/truncated N68 0.5 2 
Intrinsic 25 21 
Membrane bound 5 12 
Translocation 0.9 10 
SecA mediated bacterial translocation 0.25 4 
In vivo 
(MIC95) 
E. coli NR698 (leaky mutant) 3.1 250-500 
B. Subtilis 3.1 250-500 
E. coli (Wild type) >1000 >10,000 
 
RB and EB showed IC50 values of 0.5 µM and 2 µM respectively against truncated N68. As 
shown in the Table 3, both RB and EB show increasing IC50 trends from translocation, membrane and 
intrinsic SecA. As expected, RB (25 µM) and EB (21 µM) show higher IC50 values against intrinsic SecA 
than its unregulated counterpart. The IC50 values for membrane bound SecA inhibition caused by RB and 
EB are 5 µM and 12 µM respectively. For the translocation ATPase RB shows IC50 value of 0.9 µM and 
EB shows 10 µM. Protein translocation experiments using the oocyte model show that RB and EB 
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severely inhibit SecA-dependent in vitro protein translocation of precursor proOMpA into the membrane 
vesicles with IC50 values of 0.25 µM and 4 µM respectively. As a validation of principle, the MIC values 
observed for Gram-negative bacteria (E. coli, >1 mM) are much higher than those obtained for Gram-
positive (B. subtilis, 3.1µM) and the leaky mutant (E. coli NR698, 3.1µM), suggesting that outer cellular 
membrane in Gram-negative bacteria acts as a barrier to inhibitor permeability. 
1.1.4 Future directions  
With the urgent need of developing new antimicrobials with novel mechanisms of action, SecA 
has emerged as a promising target. There are several aspects to targeting SecA. First, the target, SecA, is 
very novel and has never been successfully explored for antimicrobial development.86 Although the 
importance of the secretory machinery such as SecA is obvious in bacterial survival, work in this area has 
been very limited because of the high degree of difficulty and lack of lead compounds. Second, promising 
leads have been identified. Third, the concept of antimicrobial effects through inhibition of SecA has 
been demonstrated. Fourth, bacterial SecA is involved in virulence factors secretion, inhibition of which 
can greatly attenuate pathogenicity.87-90 Fifth, SecA functions as a membrane protein that spans the 
bacterial membrane and forms a channel.68,91 In Gram-positive bacteria, this means that the target may be 
directly accessible from the extracellular matrix. If this is true, one can envision the design of drugs that 
enter the target directly from the extracellular matrix and exert their effect without actually entering the 
cell. The advantage of such a situation is the avoidance of the effect of efflux transporters in bacteria, the 
expression of which is a major mechanism for the development of multi-drug resistance (MDR)92-98. 
Given the wide-spread nature of efflux in bacteria and its importance in drug-resistance, such a finding by 
itself would be of extraordinary novelty and significance. We hope this review will help stimulate more 
research in this area so that new antimicrobials can be obtained by targeting SecA. 
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1.2 Results and Discussions  
1.2.1 Chemistry 
In our earlier virtual screening efforts, two hits, 8 (SEW-05929) and 9 (HTS-12302), were shown 
to have modest SecA inhibitory activities (IC50 values of about 100 μM).99, 100 Another hit 12, which was 
obtained from random screening, showed good SecA inhibitory activities (IC50 values of about 45 μM). 
Our effort to search for potent SecA inhibitors started with the optimization of these three inhibitors 
(Figure 1.8). Since at the starting point of our studies, there were no other known SecA inhibitors except 
one natural product, for which the true inhibition mechanism was not known.101  
 
Figure 1.8. Hit compounds and their derivatives 
Our optimization effort first started with the isoxazole carboxamide series (8) with the focus 
being on optimizing the aryl group attached to the amide.  In this series, 14 analogs were synthesized.  
The synthesis began with conversion of halogenated benzaldehyde 17 to the corresponding oxime 18 
(Scheme 1.1). Isoxazole acid 20 was prepared by reacting 19 with ethyl acetoacetate followed by 
hydrolysis.102 Subsequent coupling/amidation reactions using EDCI and DMAP gave the final isoxazole 
carboxamide derivatives 21a-n. In this series, there are amides of aniline compounds 21a,e,f,h,i,k,l, 
benzylamines 21b,m, secondary alkyamines 21c,d,j, and primary alkylamines 21g,n. 
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Scheme 1.1. Synthesis of isoxazole carboxamides 21a-n.  
Reagents and conditions: (a) HONH2•HCl, NaOH, EtOH, H2O, reflux; (b) NCS, DMF; (c) Ethyl acetoacetate, MeONa, THF; (d) NaOH, EtOH, 
H2O; (e) EDCI, HOBt, DMAP, DMF 
In optimizing the second series (9, Figure 1.8), we first started by testing different aryl structures 
flanking the central ring.  In our initial effort, 6-chloro-2-mercaptobenzothiazole and 2-
mercaptobenzoxazole derivatives were prepared by reacting potassium ethylxanthate 22 with 2,4-
dichloroaniline 23 or substituted 2-aminophenol 24 (Scheme 1.2). Further, 5-cyano-6-aryl-2-thiouracils 
were prepared by condensation of an aldehyde with ethyl cyanoacetate and thiourea in the presence of 
piperidine.103 The symmetrical compounds 29a-g or 30a-i were obtained by reacting two equivalents of 
compounds25a-g or 28a-i with p-xylylene dibromide in acetonitrile in the presence of K2CO3 (Scheme 3). 
One successful series of analogs was the 2,2'-(α,α’-xylene)bis(sulfanediyl)bis-(6-aryl-5-cyano-4-
oxopyrimidine) 30a-i (see below for biological results). For this series, we were interested in further 
simplifying the structure to understand the core structural need. Therefore, "monomer" series 31d,e,g-i 
was prepared by benzylation of compounds 28d,e,g-i with benzyl chloride, and the difference in activities 
between the "dimer" and "monomer" series was also studied. 
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Scheme 1.2. Synthesis of compounds 25a-g and 28a-i.  
Reagents and conditions: (a) EtOH, reflux; (b) piperidine, EtOH, reflux 
 
Scheme 1.3. Synthesis of compounds 29a-g, 30a-i and 31d,e,g-i.  
Reagents and conditions: (a) K2CO3, CH3CN, reflux 
1.2.2 Biological evaluation 
1.2.2.1 In vitro study 
The synthesized compounds were first evaluated using EcN68 SecA, which is a truncated version 
without the C-terminal regulatory/inhibitory domain, by following procedures published earlier.99 Briefly, 
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ATPase activities were determined by the release of phosphate (Pi), which can be detected spectrophoto-
spectrophotometrically using malachite green.101 For compounds 21a-n, none of them showed improved 
activities over the original hit (8) or significant inhibition at 100 μM (Figure 1.9). Such results coupled 
with the weak activities of the original hit compound led to the decision of not pursuing this class of 
compounds any further. 
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Figure 1.9. Inhibitory effect of compounds 8 and 21a-n at 100 μM against EcN68 Sec A. 
For analogs of 9, compounds 29a-g did not show significant improvement over the initial hit. 
However, the substituted thiouracils (30) showed very significant activities when screened at 100 and 30 
μM (Figure 1.10). Those compounds that showed potent inhibition at 30 μM were further screened at 5 
μM (Figure 1.11). Within the symmetrical compound series 30a-i, there are two substitution patterns: one 
with a phenyl ring substituted at the 4-position and the other with a phenyl ring substituted at the 3-
position. The results showed that the 4-substituted analogs were more potent than the 3-substituted class, 
which was in turn slightly more potent than the ones without phenyl substituent. For example the 
activities of the 4-methyl substituted (30c, Figure 1.10) was higher than the 3-methyl analog (30b, Figure 
1.10), which was in turn higher than the un-substituted one (30a, Figure 1.10). With the initial indication 
that derivatives with a phenyl ring bearing a 4-substituent were more active, the subsequent effort was 
focused on optimizing this series of compounds. One approach adopted was to use relatively bulky alkyl 
groups at the 4-position. It turned out that these compounds were more potent than the corresponding 4-
methyl substituted compounds. Among these compounds, those with an electron donating (e.g., methoxy) 
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substituent seemed to be less active than the un-substituted ones (e.g., 30f < 30a, Figure 1.10). At 5 μM, 
analogs with a halogen or aryl group substitution at the 4-position were more potent than the analogues 
with an alkyl substitution (e.g., 30g,h,i > 30c,d,e Figure 1.11). For the examination of the difference 
between the “dimers” and “monomers”, S-benzyl-2-thiouracils analogues 31d, e, g-i were also tested 
(Figure 1.12). First of all, both thiouracil-based “dimer” and “monomer” compounds showed more potent 
inhibition than the benzothiazole or benzoxazole compounds 29a-g. 
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Figure 1.10. Inhibitory effect of compounds 30a-i at 30 μM against EcN68 Sec A. 
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Figure 1.11. Inhibitory effect of compounds 30c-e, g-i at 5 μM against EcN68 Sec A. 
However, the "dimer" series 30d,e,g-i were more potent than the "monomer" series 31d,e,g-i, 
respectively. This higher potency for the “dimer” series seems to come from better fitting of the binding 
pocket of these compounds (see below). In the “monomer” series, it was observed that a large sized R’ 
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group seemed to confer high potency (e.g., 31h > 31g ≈ 31e > 31d). However, when the substituented 
phenyl ring was replaced by a larger 1-naphthyl group, the activity seemed to decrease slightly. 
co
ntr
ol 31
d 31
e
31
g
31
h 31
i
0
25
50
75
100
A
ct
iv
ity
 (%
)
 
Figure 1.12. Inhibitory effect of compounds 31d, e, g-i at 30 μM against EcN68 Sec A. 
We determined the IC50 values of compound 30 g and 30 h since they showed the most potent 
activities of all the compounds screened at 5 μM. The result showed they had low micro molar inhibition 
(IC50: 2 μM, Figure 1.13), which is 50-fold more potent than the hit compound 9 (IC50: 100 μM).99 
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Figure 1.13. The inhibitory curves of the two most potent compounds, 30g and 30h, against EcN68 Sec A. 
Inhibition tests using whole EcSecA gave similar results (30g IC50: 20 μM, 30h IC50: 50 μM and 
31h IC50: 60 μM, Figure 1.14), which suggest that the EcN68 inhibition assay is more sensitive than the 
whole SecA inhibition assay. This is understandable since EcSecA contains a regulatory domain, which is 
essentially an inhibitor. 
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Figure 1.14. The inhibitory curves of 30g,h and 31h against EcSecA. 
1.2.2.2 In vivo study 
The biological activities of “dimer” and “monomer” compounds 30h and 31h were assessed 
against leaky mutant NR698 and wild type E. coli strain MC4100 by determining the minimum inhibition 
concentration (MIC) (Figure 1.15). “Monomer” compound 31h exhibited the most potent inhibition 
effects against NR698, whereas “dimer” compounds 30h did not exhibit significantly antimicrobial 
activities. However, neither 31h nor 30h exhibited inhibition effects against wild type E. coli strain 
MC4100. Such results suggest that the permeability of 30h against NR698 and 31h against MC4100 
might be a key factor and for in vivo applications future studies should focus on low molecular weight 
compounds such as 31h for structural optimization. 
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Figure 1.15. The inhibitory curves of 30g,h and 31h against bacterial growth. 
1.2.3 Computational modeling 
In order to achieve a detailed understanding the binding mode between SecA and our compounds, 
in silico modeling was conducted by using molecular simulation.104-107 Herein, the parent compound, 
HTS-12302 and the most active compound, 30g, were docked into the ATP site of SecA using DOCK 5.4. 
The docked complexes were then optimized by molecular mechanics and molecular dynamics simulation 
implemented in AMBER 8. Finally, the possible ligand-protein interactions were examined by following 
similar procedures we used in previous studies.99 After molecular simulation, compound HTS-12302 
seems to bind SecA through interactions with Thr 104 by forming hydrogen bond and with Met 81, Phe 
84, Gln 87, Gly 105, Glu 106, Gly 107, Lys 108, Thr 109, Leu 110, Gly 392 and Arg 509 through 
hydrophobic interactions (Figure 9). Compound 30g has a similar binding conformation and orientation, 
in which it seems to engage in more hydrogen bond interactions with Phe 84, Gln 87, Lys 108 and Glu 
210. Moreover, compound 30g still bears hydrophobic interactions with Met 81, Thr 104, Gly 105, Glu 
106, Gly 107, Leu 110 and Arg 509. Upon analysis of the structural features of these two compounds, it 
seems that the inclusion of the thiouracil moiety may contribute to the inhibitory activity because of more 
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hydrophobic interaction and hydrogen bonds when compared with lead compound HTS-12302. Such 
structural insights will play a very critical role in future design of potent SecA inhibitors and in further 
structural optimizations. 
 
Figure 1.16. (A) The proposed docking conformation of HTS-12302 (white sticks) and compound 30g 
(green sticks) around SecA ATP-site; (B) The proposed schematic interactions of HTS-12302 with SecA; 
(C) The proposed schematic interactions of compound 30g with SecA 
1.3 Experimental part 
1.3.1 Chemistry 
General Chemical Methods. All reagents and solvents were reagent grade or were purified by 
standard methods before use. Column chromatography was carried out on flash silica gel (Sorbent 230-
400 mesh). TLC analysis was conducted on silica gel plates (Sorbent Silica G UV254). NMR spectra 
were recorded at 1H (400 MHz) and 13C (100 MHz) with a Bruker instrument. Chemical shifts (δ values) 
and coupling constants (J values) are given in ppm and Hz, respectively, using TMS (1H NMR) and 
solvents (13C NMR) as internal standards. 
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General procedure for the preparation of isoxazole carboxamide derivatives (21a-n). Under 
N2 atmosphere, a solution of an isoxazole carboxylic acid (6, 0.1 mmol), amine (0.12 mmol), EDCI (23 
mg, 0.12 mmol), DMAP (14.7 mg, 0.12 mmol) and HOBt (27 mg, 0.2 mmol) in DMF (2.5 mL) was 
stirred at room temperature overnight. Then most of the solvent was removed under reduced pressure. To 
the residue was added 10 mL H2O and 10 mL EtOAc. Then the aqueous solution was extract by EtOAc 
(20 mL × 2).  The organic layer was subsequently washed with brine (20 mL). The crude compound was 
purified by flash chromatography on silica gel using hexane and EtOAc (9:1) as the mobile phase to give 
7a-7n. 
3-(2,6-Dichlorophenyl)-5-methyl-N-m-tolylisoxazole-4-carboxamide (21a). Yield 76%; 1H 
NMR (CDCl3) δ 1.70 (s, 3H), 2.86 (s, 3H), 6.74 (bs, 1H), 7.00-7.07 (m, 2H), 7.18 (td, 1H, J = 1.6 Hz, 7.2 
Hz), 7.44 (dd, 1H, J = 6.4 Hz, 9.6 Hz), 7.50 (m, 2H), 7.90 (d, 1H, J = 8.0 Hz); 13C NMR (CDCl3) δ 13.7, 
16.9, 112.0, 123.0, 125.4, 127.0, 127.3, 128.3, 129.1, 130.6, 132.7, 135.3, 136.6, 155.7, 159.0, 176.4. 
HRMS-ESI (+): Calc. for C18H15N2O2Cl2: 361.0511. Found: 361.0527 [M+H]+. 
N-(3-Bromobenzyl)-3-(2,6-dichlorophenyl)isoxazole-4-carboxamide (21b). Yield 71%; 1H 
NMR (CDCl3) δ 2.27 (s, 3H), 2.84 (s, 3H), 6.85 (m, 3H), 7.11 (m, 2H), 7.48 (dd, 1H, J = 6.4 Hz, 9.6 Hz), 
7.54 (m, 2H); 13C NMR (CDCl3) δ 13.5, 21.7, 112.1, 117.1, 120.8, 125.8, 127.3, 129.0, 129.0, 132.7, 
136.4, 137.2, 139.3, 155.9, 158.9, 175.7. HRMS-ESI (+): Calc. for C18H15N2O2Cl2: 361.0511. Found: 
361.0516 [M+H]+. 
(3-(2,6-Dichlorophenyl)-5-methylisoxazol-4-yl)(morpholino)methanone (21c). Yield 81%; 1H 
NMR (CDCl3) δ 1.63 (s, 3H), 2.18 (s, 3H), 2.80 (s, 3H), 6.62 (bs, 1H), 6.82 (s, 1H), 6.92 (d, 1H, J = 8.4 
Hz), 7.37 (dd, 1H, J = 6.4 Hz, 9.6 Hz), 7.44 (m, 2H), 7.66 (d, 1H, J = 8.4 Hz); 13C NMR (CDCl3) δ 13.7, 
16.9, 21.0, 112.0, 123.2, 127.4, 127.5, 128.6, 129.0, 131.2, 132.7, 135.3, 136.6, 155.7, 159.0, 176.2. 
HRMS-ESI (+): Calc. for C19H17N2O2Cl2: 375.0667. Found: 375.0679 [M+H]+. 
(3-(2,6-Dichlorophenyl)-5-methylisoxazol-4-yl)(piperidin-1-yl)methanone (21d). Yield 67%; 
1H NMR (CDCl3) δ 2.24 (s, 3H), 2.78 (s, 3H), 6.70 (dd, 1H, J = 2.4 Hz, 8.4 Hz), 6.75 (bs, 1H), 7.12 (d, 
1H, J = 2.4 Hz), 7.29 (d, 1H, 8.8 Hz), 7.43 (dd, 1H, J = 6.4 Hz, 9.6 Hz), 7.49 (m, 2H), 7.62 (m, 5H); 13C 
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NMR (CDCl3) δ 13.6, 23.3, 111.9, 118.8, 120.1, 122.2, 127.2, 129.0, 132.8, 132.8, 136.3, 136.5, 139.0, 
155.8, 158.8, 175.9. HRMS-ESI (+): Calc. for C18H14N2O2Cl2Br: 438.9616. Found: 438.9633 [M+H]+. 
3-(2,6-Dichlorophenyl)-N-(2,4-dimethylphenyl)-5-methylisoxazole-4-carboxamide (21e). 
Yield 55%; 1H NMR (CDCl3) δ 2.87 (s, 3H), 6.92-6.99 (m, 2H), 7.08 (t, 1H, J = 7.6 Hz), 7.20 (bs, 1H), 
7.47 (dd, 1H, J = 6.4 Hz, 9.6Hz), 7.52 (m, 2H), 8.33 (td, 1H, J = 1.6 Hz, 8.0 Hz); 13C NMR (CDCl3) δ 
13.7, 111.8, 114.7, 114.9, 121.6, 124.7, 124.8, 124.8, 124.8, 126.3, 129.1, 132.8, 136.3, 153.4, 155.9, 
158.8, 176.4. HRMS-ESI (+): Calc. for C17H12N2O2Cl2F: 365.0260. Found: 365.0269 [M+H]+. 
N-(3-Chlorophenyl)-3-(2,6-dichlorophenyl)-5-methylisoxazole-4-carboxamide (21f). Yield 
42%; 1H NMR (CDCl3) δ 2.79 (s, 3H), 6.81 (bs, 1H), 6.84 (m, 1H), 6.98 (m, 1H), 7.09 (t, 1H, J = 8.0 Hz), 
7.30 (t, 1H, J = 1.6 Hz), 7.45(dd, 1H, J = 6.4 Hz, 9.6 Hz), 7.50 (m, 2H); 13C NMR (CDCl3) δ 90.2, 113.8, 
128.2, 128.6, 132.0, 158.2, 160.2, 176.0. HRMS-ESI (+): Calc. for C17H12N2O2Cl3: 380.9964. Found: 
380.9962 [M+H]+. 
N-Cyclohexyl-3-(2,6-dichlorophenyl)-5-methylisoxazole-4-carboxamide (21g). Yield 59%; 1H 
NMR (CDCl3) δ 2.83 (s, 3H), 6.83 (bs, 1H), 6.87 (m, 1H), 6.98 (t, 1H, J = 8.8 Hz), 7.42 (dd, 1H, J = 2.8 
Hz, 6.8 Hz), 7.50 (dd, 1H, J = 6.4 Hz, 9.6 Hz), 7.55 (m, 2H); 13C NMR (CDCl3) δ 13.6, 111.7, 116.8, 
117.0, 119.6, 119.7, 121.4, 121.6, 122.4, 127.1, 129.1, 132.9, 133.8, 136.3, 154.0, 155.7, 156.4, 158.9, 
176.1. HRMS-ESI (+): Calc. for C17H11N2O2FCl3: 398.9870. Found: 398.9885 [M+H]+. 
3-(2,6-Dichlorophenyl)-5-methyl-N-o-tolylisoxazole-4-carboxamide (21h). Yield 79%; 1H 
NMR (CDCl3) δ 0.83 (m, 2H), 1.04 (m, 1H), 1.19-1.32 (m, 4H), 1.39 (m, 1H), 2.02 (m, 2H), 2.73 (s, 3H), 
3.74 (m, 1H), 5.02 (m, 1H), 7.39 (dd, 1H, J = 6.4 Hz, 9.6 Hz), 7.45 (m, 2H); 13C NMR (CDCl3) δ 13.3, 
24.1, 25.5, 32.5, 47.4, 112.0, 127.8, 128.7, 132.4, 136.3, 156.1, 159.9, 174.7. HRMS-ESI (+): Calc. for 
C17H19N2O2Cl2: 353.0824. Found: 353.0838 [M+H]+. 
N-(4-Bromo-3-methylphenyl)-3-(2,6-dichlorophenyl)-5-methylisoxazole-4-carboxamide (21i). 
Yield 82%; 1H NMR (CDCl3) δ 0.28 (m, 2H), 0.65-0.70 (m, 4H), 0.81 (d, 2H, J = 6.8 Hz), 0.94 (m, 2H), 
1.16-1.25 (m, 2H), 1.31-1.44 (m, 4H), 1.49-1.58 (m, 4H), 1.75 (m, 2H), 3.63 (m, 1H), 4.10 (m, 1H), 7.39-
7.51 (m, 5H); 13C NMR (CDCl3) δ13.2, 13.4, 22.2, 22.3, 29.6, 29.8, 31.5, 31.9, 32.9, 33.6, 44.3, 48.3, 
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111.8, 112.0, 127.7, 127.9, 128.7, 128.9, 132.3, 132.6, 136.2, 136.4, 156.0, 156.2, 159.8, 160.0, 174.5, 
175.3. HRMS-ESI (+): Calc. for C18H21N2O2Cl2: 367.0980. Found: 367.0991 [M+H]+. 
(3-(2,6-Dichlorophenyl)-5-methylisoxazol-4-yl)(thiomorpholino)methanone (21j). Yield 85%; 
1H NMR (CDCl3) δ 1.34 (bs, 4H), 1.52 (m, 2H), 2.56 (s, 3H), 3.38 (bs, 4H), 7.32 (m, 1H), 7.40 (m, 2H); 
13C NMR (CDCl3) δ 12.4, 24.4, 25.9, 113.6, 127.7, 128.4, 131.5, 135.9, 157.5, 161.6, 169.6. HRMS-ESI 
(+): Calc. for C16H17N2O2Cl2: 339.0667. Found: 339.0668[M+H]+. 
3-(2,6-Dichlorophenyl)-N-(2-fluorophenyl)-5-methylisoxazole-4-carboxamide (21k). Yield 
84%; 1H NMR (CDCl3) δ 2.52 (s, 3H), 3.36 (bs, 8H), 7.30 (dd, 1H, J = 6.4 Hz, 9.6Hz), 7.37 (m, 2H); 13C 
NMR (CDCl3) δ 12.6, 66.7, 112.8, 127.4, 128.6, 131.8, 135.9, 157.3, 161.9, 170.4. HRMS-ESI (+): Calc. 
for C15H15N2O3Cl2: 341.0460. Found: 341.0466 [M+H]+. 
N-(3-Chloro-4-fluorophenyl)-3-(2,6-dichlorophenyl)-5-methylisoxazole-4-carboxamide (21l). 
Yield 72%; 1H NMR (CDCl3) δ 2.30 (bs, 4H), 2.52 (s, 3H), 3.62 (bs, 4H), 7.30 (dd, 1H, J = 6.4 Hz, 
9.6Hz), 7.37 (m, 2H); 13C NMR (CDCl3) δ 12.6, 27.8, 113.0, 127.4, 128.6, 131.9, 135.9, 157.2, 162.2, 
170.4. HRMS-ESI (+): Calc. for C15H15N2O2SCl2: 357.0231. Found: 357.0237 [M+H]+. 
N-(2-Bromobenzyl)-3-(2,6-dichlorophenyl)-5-methylisoxazole-4-carboxamide (21m). Yield 
73%; 1H NMR (CDCl3) δ 2.73 (s, 3H), 4.37 (d, 2H, J = 6.0 Hz), 5.62 (bs, 1H), 7.04 (m, 1H), 7.16 (m, 2H), 
7.26-7.33 (m, 3H), 7.38 (d, 1H, J = 8.0 Hz); 13C NMR (CDCl3) δ 13.4, 43.9, 111.6, 123.9, 127.3, 127.9, 
128.8, 129.5, 130.6, 132.3, 132.8, 136.2, 136.9, 156.1, 160.6, 175.2. HRMS-ESI (+): Calc. for 
C18H14N2O2Cl2Br: 438.9616. Found: 438.9627 [M+H]+. 
3-(2,6-Dichlorophenyl)-5-methyl-N-(4-methylcyclohexyl)isoxazole-4-carboxamide (mixture 
of cis & trans) (21n). Yield 93%; 1H NMR (CDCl3) δ 2.74 (s, 3H), 4.28 (d, 2H, J = 5.6 Hz), 5.27 (bs, 
1H), 6.91 (d, 1H, J = 7.2 Hz), 7.04 (m, 2H), 7.29 (d, 2H, J = 7.6 Hz), 7.34 (d, 2H, J = 7.6 Hz); 13C NMR 
(CDCl3) δ 13.4, 42.9, 111.5, 122.9, 126.2, 127.3, 128.8, 130.2, 130.4, 132.5, 136.0, 139.8, 156.1, 160.7, 
175.2. HRMS-ESI (+): Calc. for C18H14N2O2Cl2Br: 438.9616. Found: 438.9635 [M+H]+. 
General procedures for the preparation of and 2-mercaptobenzoxazole (25b-g). To a solution 
of a substituted 2-aminophenol (3 mmol) was added potassium ethylxanthate (484 mg, 3 mmol) in 
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absolute ethanol (10 mL). The resulting mixture was heated under reflux overnight and then cooled to 
room temperature. The precipitate was dissolved in H2O (10 mL) and washed with ethyl acetate (10 mL × 
3) and the aqueous solution was then neutralized to pH = 5 by slow addition of glacial acetic acid. Then 
the product precipitated (crystallized) out to give 25b-g. 
2-Mercaptobenzoxazole (25b). Yield 52%; 1H NMR (DMSO-d6) δ 7.29 (m, 3H), 7.53 (d, 1H, J 
= 7.6 Hz), 13.90 (bs, 1H); 13C NMR (DMSO-d6) δ 110.0, 110.5, 123.7, 125.1, 131.2, 148.1, 180.1. 
HRMS-ESI (+): Calc. for C7H6NOS: 152.0170. Found: 152.0170 [M+H]+. 
2-Mercapto-5-methylbenzoxazole (25c). Yield 45%; 1H NMR (DMSO-d6) δ 2.37 (s, 3H), 7.05 
(m, 2H), 7.34 (m, 1H), 13.73 (bs, 1H); 13C NMR (DMSO-d6) δ 20.8, 109.4, 110.4, 124.2, 131.2, 134.7, 
146.3, 180.2. HRMS-ESI (+): Calc. for C8H8NOS: 166.0327. Found: 166.0333 [M+H]+. 
2-Mercapto-6-methylbenzoxazole (25d). Yield 64%; 1H NMR (DMSO-d6) δ 2.39 (s, 3H), 7.10 
(d, 1H, J = 7.6 Hz), 7.16 (t, 1H, J = 7.6 Hz), 7.31 (d, 1H, J = 7.6 Hz), 13.95 (bs, 1H); 13C NMR (DMSO-
d6) δ 16.1, 107.2, 121.1, 123.6, 126.0, 130.4, 147.9, 180.1. HRMS-ESI (+): Calc. for C8H8NOS: 166.0327. 
Found: 166.0333 [M+H]+. 
2-Mercapto-3-nitrobenzoxazole (25e). Yield 14%; 1H NMR (DMSO-d6) δ 7.44 (t, 1H, J = 
8.0Hz), 7.91 (d, 1H, J = 8.0 Hz), 8.06 (d, 1H, J = 8.0 Hz); 13C NMR (DMSO-d6) δ 115.8, 119.8, 123.4, 
128.0, 131.4, 149.8, 181.7. HRMS-ESI (+): Calc. for C7H5N2O3S: 197.0021. Found: 197.0013 [M+H]+. 
2-Mercapto-5-nitrobenzoxazole (25f). Yield 25%; 1H NMR (DMSO-d6) δ 7.17 (d, 1H, J = 8.8 
Hz), 7.95 (d, 1H, J = 2.4 Hz), 7.99 (dd, 1H, J = 2.4 Hz, 8.8 Hz); 13C NMR (DMSO-d6) δ 101.8, 112.3, 
119.8, 139.7, 150.3, 153.2, 188.4. HRMS-ESI (+): Calc. for C7H5N2O3S: 197.0021. Found: 197.0018 
[M+H]+. 
2-Mercapto-5-chlorobenzoxazole (25g). Yield 36%; 1H NMR (DMSO-d6) δ 7.30 (d, 2H, J = 7.6 
Hz), 7.53 (d, 1H, J = 8.0 Hz), 14.04 (bs, 1H); 13C NMR (DMSO-d6) δ 110.3, 111.2, 123.5, 129.3, 132.6, 
147.0, 180.8. HRMS-ESI (+): Calc. for C7H5NOSCl: 185.9780. Found: 185.9789 [M+H]+. 
General procedures for the preparation of 2-thiouracils 28a-i. To a solution of an aldehyde 
(RCHO, 10 mmol), ethyl cyanoacetate (1.0 mL, 10 mmol), and thiourea (0.76 g, 10 mmol) in absolute 
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ethanol (50 mL) was added piperidine (2.0 mL, 20 mmol); the mixture was heated under reflux overnight 
and then cooled to room temperature. The precipitate was dissolved in 0.5M NaOH (20 mL) and washed 
with ethyl acetate (10 mL × 3). The aqueous solution was then neutralized to pH = 2 by slow addition of 
1M HCl. Then the product precipitated (crystallized) out to give 28a-i. 
5-Cyano-6-phenyl-2-thiouracil (28a). Yield 67%; 1H NMR (DMSO-d6) δ 7.62 (m, 5H), 13.19 (s, 
1H), 13.32 (bs, 1H); 13C NMR (DMSO-d6) δ 90.2, 113.8, 128.2, 128.6, 132.0, 158.2, 160.2, 176.0. MS-
ESI (+): 252.0 [M+Na]+. 
5-Cyano-6-(3-tolyl)-2-thiouracil (28b). Yield 31%; 1H NMR (DMSO-d6) δ 2.39 (s, 3H), 7.46 (m, 
4H), 13.17 (s, 1H), 13.26 (bs, 1H); 13C NMR (DMSO-d6) δ 20.9, 90.6, 114.7, 125.9, 128.4, 129.1, 129.2, 
132.8, 137.9, 158.5, 160.9, 176.2. HRMS-ESI (+): Calc. for C12H10N3OS: 244.0545. Found: 244.0555 
[M+H]+. 
5-Cyano-6-(4-tolyl)-2-thiouracil (28c). Yield 43%; 1H NMR (DMSO-d6) δ 2.45 (s, 3H), 7.41 (d, 
2H, J = 7.6 Hz), 7.61 (d, 2H, J = 8.4 Hz); 13C NMR (DMSO-d6) δ 12.2, 81.7, 105.9, 118.4, 120.1, 121.2, 
135.3, 150.9, 153.2, 168.2. HRMS-ESI (+): Calc. for C13H12N3OS: 258.0701. Found: 258.0702 [M+H]+. 
5-Cyano-6-(4-ethylphenyl)-2-thiouracil (28d). Yield 25%; 1H NMR (DMSO-d6) δ 1.22 (t, 3H, J 
= 7.6 Hz), 2.71 (q, 2H, J = 7.6 Hz), 7.42 (d, 2H, J = 8.0 Hz), 7.61 (d, 2H, J = 8.0 Hz), 13.15 (bs, 1H); 13C 
NMR (DMSO-d6) δ 15.2, 28.1, 90.4, 114.8, 126.6, 127.9, 128.9, 148.6, 158.5, 160.9, 176.2. HRMS-ESI 
(+): Calc. for C14H14N3OS: 272.0858. Found: 272.0867 [M+H]+. 
5-Cyano-6-(4-isopropylphenyl)-2-thiouracil (28e). Yield 37%; 1H NMR (DMSO-d6) δ 1.24 (d, 
6H, J = 6.8 Hz), 3.00 (septet, 1H, J = 6.8 Hz), 7.46 (d, 2H, J = 8.0 Hz), 7.62 (d, 2H, J = 8.0 Hz), 13.15 (bs, 
2H); 13C NMR (DMSO-d6) δ 23.6, 33.5, 90.3, 114.9, 126.5, 126.7, 129.0, 153.1, 158.6, 160.8, 176.2. 
HRMS-ESI (+): Calc. for C14H14N3OS: 272.0858. Found: 272.0867 [M+H]+. 
5-Cyano-6-(4-methoxyphenyl)-2-thiouracil (28f). Yield 21%; 1H NMR (DMSO-d6) δ 3.86 (s, 
3H), 7.12 (d, 2H, J = 8.8 Hz), 7.68 (d, 2H, J = 8.8 Hz), 13.13 (bs, 2H); 13C NMR (DMSO-d6) δ 55.7, 89.9, 
114.0, 115.2, 121.1, 131.0, 158.8, 160.6, 162.5, 176.3. HRMS-ESI (+): Calc. for C12H10N3O2S: 260.0494. 
Found: 260.0496 [M+H]+. 
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5-Cyano-6-(4-bromophenyl)-2-thiouracil (28g). Yield 39%; 1H NMR (DMSO-d6) δ 7.63 (d, 2H, 
J = 8.4 Hz), 7.80 (d, 2H, J = 8.4 Hz), 13.21 (s, 1H), 13.37 (bs, 1H); 13C NMR (DMSO-d6) δ 91.1, 114.6, 
125.9, 128.5, 130.9, 131.6, 158.4, 160.0, 176.2. HRMS-ESI (+): Calc. for C11H7N3OSBr: 307.9493. 
Found: 307.9504 [M+H]+. 
5-Cyano-6-(biphenyl-4-yl)-2-thiouracil (28h). Yield 75%; 1H NMR (DMSO-d6) δ 7.45 (t, 1H, J 
= 7.2 Hz), 7.53 (t, 2H, J = 7.2 Hz), 7.78 (d, 4H, J = 8.4 Hz), 7.89 (d, 2H, J = 8.4Hz) 13.19 (s, 1H), 13.35 
(bs, 1H); 13C NMR (DMSO-d6) δ 90.6, 114.8, 126.6, 127.0, 128.1, 128.4, 129.2, 129.6, 138.7, 143.7, 
158.5, 160.5, 176.2. HRMS-ESI (+): Calc. for C17H12N3OS: 306.0701. Found: 306.0714 [M+H]+. 
5-Cyano-6-(1-naphthyl)-2-thiouracil (28i). Yield 22%; 1H NMR (DMSO-d6) δ 7.64 (m, 3H), 
7.74 (d, 1H, J = 6.8 Hz), 7.99 (dd, 1H, J = 6.0 Hz, 6.4 Hz), 8.06 (dd, 1H, J = 6.0 Hz, 6.4 Hz, ), 8.15 (d, 
1H, J = 8.4 Hz), 13.11 (s, 1H), 13.46 (bs, 1H); 13C NMR (DMSO-d6) δ 93.1, 114.5, 124.7, 125.2, 126.8, 
127.2, 127.5, 128.3, 128.5, 129.5, 131.2, 132.8, 158.7, 161.1, 176.8. HRMS-ESI (+): Calc. for 
C15H10N3OS: 280.0545. Found: 280.0554 [M+H]+. 
General procedure for the preparation of 2,2'-(α,α’-Xylene)bis(sulfanediyl)bisbenzothiazole 
(29a), 2,2'-(α,α’-Xylene)bis(sulfanediyl)bisbenzoxazole (29b-g), and 2,2'-(α,α’-
Xylene)bis(sulfanediyl)bis-4-oxopyrimidine (30a-i). To a solution of the 2-mercaptobenzothiazole, 2-
mercaptobenzoxazole, or 2-thiouracil derivatives (25a-g or 28a-h, 0.1 mmol) and α, α’-xylenedibromide 
(12 mg, 0.045 mmol) in acetonitrile (2.5 mL) was added K2CO3 (42 mg, 0.3 mmol).  The mixture was 
heated under reflux overnight and then cooled to room temperature. The liquid was removed on a 
rotavapor and the residue was washed with 0.5M NaOH (20 mL). Then the white solid residue was dried 
in vacuum oven at 40 ºC overnight to give 29a-g or 30a-h. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(6-chlorobenzothiazole) (29a). Yield 84%; 1H NMR 
(DMSO-d6) δ 4.62 (s, 4H), 7.45 (s, 4H), 7.47 (dd, 2H, J = 2.0 Hz, 8.4 Hz), 7.84 (d, 2H, J = 8.4 Hz), 8.11 
(d, 2H, J = 2.0 Hz); 13C NMR (DMSO-d6) δ 36.3, 120.8, 121.7, 126.2, 128.7, 135.4, 135.9, 151.0, 166.6. 
HRMS-ESI (+): Calc. for C22H15N2S4Cl2: 504.9495. Found: 504.9499 [M+H]+. 
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2,2'-(α,α’-Xylene)bis(sulfanediyl)bis(benzoxazole) (29b). Yield 35%; 1H NMR (DMSO-d6) δ 
4.60 (s, 4H), 7.34 (m, 4H), 7.49 (m, 4H), 7.65 (m, 4H); 13C NMR (DMSO-d6) δ 35.1, 110.2, 118.3, 124.3, 
124.6, 129.2, 136.1, 141.2, 151.3, 163.8. HRMS-ESI (+): Calc. for C22H17N2O2S2: 405.0731. Found: 
405.0732[M+H]+. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(5-methylbenzoxazole) (29c). Yield 57%; 1H NMR 
(DMSO-d6) δ 2.40 (s, 6H), 4.57 (s, 4H), 7.12 (d, 2H, J = 8.0 Hz), 7.46 (m, 8H); 13C NMR (DMSO-d6) δ 
20.9, 35.1, 109.6, 118.3, 125.1, 129.2, 134.0, 136.2, 141.4, 149.5, 163.6. HRMS-ESI (+): Calc. for 
C24H21N2O2S2: 433.1044. Found: 433.1041 [M+H]+. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(6-methylbenzoxazole) (29d). Yield 86%; 1H NMR 
(DMSO-d6) δ 2.49 (s, 6H), 4.59 (s, 4H), 7.18 (m, 4H), 7.43 (d, 2H, J = 7.6 Hz), 7.49 (s, 4H); 13C NMR 
(DMSO-d6) δ 16.0, 35.2, 107.5, 124.0, 125.1, 128.3, 129.3, 136.2, 140.4, 151.0, 162.6. HRMS-ESI (+): 
Calc. for C24H21N2O2S2: 433.1044. Found: 433.1050 [M+H]+. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(4-nitrobenzoxazole) (29e). Yield 61%; 1H NMR 
(DMSO-d6) δ 4.66 (s, 4H), 7.50 (t, 4H, J = 8.0 Hz), 7.52 (s, 4H), 8.01 (d, 2H, J = 8.0 Hz), 8.08 (d, 2H, J = 
8.0 Hz); 13C NMR (DMSO-d6) δ 35.3, 115.6, 119.8, 123.5, 128.8, 135.4, 136.9, 152.6, 168.1. HRMS-ESI 
(+): Calc. for C22H15N4O6S2: 495.0433. Found: 495.0438 [M+H]+. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(6-nitrobenzoxazole) (29f). Yield 81%; 1H NMR 
(DMSO-d6) δ 4.67 (s, 4H), 7.53 (s, 4H), 7.85 (d, 2H, J = 8.4 Hz), 8.27 (dd, 2H, J = 2.0 Hz, 8.4 Hz), 8.62 
(d, 2H, J = 2.0 Hz); 13C NMR (DMSO-d6) δ 35.4, 106.9, 118.2, 121.0, 129.4, 135.9, 143.9, 146.6, 150.6, 
170.0. HRMS-ESI (+): Calc. for C22H15N4O6S2: 495.0433. Found: 495.0431 [M+H]+. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(5-chlorobenzoxazole) (29g). Yield 49%; 1H NMR 
(DMSO-d6) δ4.60 (s, 4H), 7.36 (dd, 2H, J = 2.0 Hz, 8.8 Hz), 7.48 (s, 4H), 7.67 (d, 2H, J = 8.8 Hz), 7.76 
(d, 2H, J = 2.0 Hz); 13C NMR (DMSO-d6) δ 35.2, 111.5, 118.1, 124.3, 129.0, 129.3, 136.0, 142.5, 150.1, 
165.9.  HRMS-ESI (+): Calc. for C22H15N2O2S2Cl2: 472.9952. Found: 472.9974 [M+H]+.     
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(6-phenyl-5-cyano-4-oxopyrimidine) (30a). Yield 80%; 
1H NMR (DMSO-d6) δ 4.26 (s, 4H), 7.31 (s, 4H), 7.44 (m, 6H), 7.77 (m, 4H); 13C NMR (DMSO-d6) δ 
33 
33.6, 88.8, 119.9, 127.8, 127.9, 128.6, 129.3, 137.2, 137.7, 166.8, 170.3, 171.5. HRMS-ESI (-): Calc. for 
C30H19N6O2S2: 559.1011. Found: 559.0989 [M-H]-. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(6-(3-tolyl)-5-cyano-4-oxopyrimidine) (30b). Yield 62%; 
1H NMR (DMSO-d6) δ 2.35 (s, 6H), 4.24 (s, 4H), 7.31 (m, 8H), 7.54 (s, 4H); 13C NMR (DMSO-d6) δ 21.0, 
33.6, 88.9, 120.1, 125.3, 127.9, 128.6, 128.8, 130.2, 137.2, 137.4, 137.8, 167.2, 170.5, 171.6. HRMS-ESI 
(-): Calc. for C32H23N6O2S2: 587.1324. Found: 587.1348 [M-H]-. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(6-(4-tolyl)-5-cyano-4-oxopyrimidine) (30c). Yield 80%; 
1H NMR (DMSO-d6) δ 2.36 (s, 6H), 4.25 (s, 4H), 7.26 (d, 4H, J = 8.0 Hz), 7.32 (s, 4H), 7.68 (d, 4H, J = 
8.0 Hz); 13C NMR (DMSO-d6) δ 21.0, 33.7, 88.6, 120.2, 128.1, 128.6, 128.9, 134.9, 137.4, 139.4, 166.9, 
170.7, 171.7.  HRMS-ESI (-): Calc. for C32H23N6O2S2: 587.1324. Found: 587.1306 [M-H]-. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(6-(4-ethylphenyl)-5-cyano-4-oxopyrimidine) (30d). 
Yield 96%; 1H NMR (DMSO-d6) δ 1.21 (t, 6H, J = 7.6 Hz), 2.65 (q, 4H, J = 7.6 Hz), 4.26 (s, 4H), 7.29 (d, 
4H, J = 8.0 Hz), 7.32 (s, 4H), 7.70 (d, 4H, J = 8.0 Hz); 13C NMR (DMSO-d6) δ 15.5, 28.1, 33.7, 88.6, 
120.3, 127.5, 128.2, 128.9, 135.2, 137.4, 145.6, 166.9, 170.7, 171.7.  HRMS-ESI (-): Calc. for 
C34H27N6O2S2: 615.1637. Found: 615.1613 [M-H]-. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(6-(4-isopropylphenyl)-5-cyano-4-oxopyrimidine) (30e). 
Yield 87%; 1H NMR (DMSO-d6) δ 1.25 (d, 12H, J = 7.2 Hz), 2.98 (septet, 2H, J = 7.2 Hz), 4.52 (s, 4H), 
7.36 (s, 4H), 7.38 (d, 4H, J = 8.4 Hz), 7.87 (d, 4H, J = 8.0 Hz); 13C NMR (DMSO-d6) δ 22.7, 32.7, 33.7, 
91.8, 114.9, 125.8, 128.2, 128.4, 132.2, 135.3, 152.1, 161.1, 165.3, 166.4.  HRMS-ESI (-): Calc. for 
C36H31N6O2S2: 643.1950. Found: 643.1943 [M-H]-. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(6-(4-methoxyphenyl)-5-cyano-4-oxopyrimidine) (30f). 
Yield 46%; 1H NMR (DMSO-d6) δ 3.81(s, 6H), 4.28 (s, 4H), 6.97 (d, 4H, J = 8.8 Hz), 7.30 (s, 4H), 7.82 
(d, 4H, J = 8.8 Hz); 13C NMR (DMSO-d6) δ 33.7, 55.3, 88.2, 113.5, 120.4, 128.9, 129.8, 130.0, 137.4, 
160.6, 166.3, 170.6, 171.4.  HRMS-ESI (-): Calc. for C32H23N6O4S2: 619.1222. Found: 619.1230 [M-H]-. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(6-(4-bromophenyl)-5-cyano-4-oxopyrimidine) (30g). 
Yield 95%; 1H NMR (DMSO-d6) δ 4.25 (s, 4H), 7.31 (s, 4H), 7.67 (d, 4H, J = 8.4 Hz), 7.72 (d, 4H, J = 
34 
8.8 Hz); 13C NMR (DMSO-d6) δ 33.7, 88.9, 119.9, 123.3, 128.9, 130.2, 131.1, 136.8, 137.3, 165.9, 170.2, 
171.8.  HRMS-ESI (-): Calc. for C30H18Br2N6O2S2: 714.9221. Found: 714.9213 [M-H]-. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(6-(biphenyl-4-yl)-5-cyano-4-oxopyrimidine) (30h). 
Yield 68%; 1H NMR (DMSO-d6) δ 4.28 (s, 4H), 7.35 (s, 4H), 7.40 (t, 2H, J = 7.2 Hz), 7.49 (t, 4H, J = 7.6 
Hz), 7.75 (m, 8H), 7.88 (d, 4H, J = 8.4 Hz); 13C NMR (DMSO-d6) δ 33.7, 88.8, 120.3, 126.3, 126.8, 127.8, 
128.7, 128.9, 129.0, 136.7, 137.4, 139.5, 141.3, 166.4, 170.4, 171.8.  HRMS-ESI (-): Calc. for 
C42H27N6O2S2: 711.1637. Found: 711.1661 [M-H]-. 
2,2'-(α,α’-Xylene)bis(sulfanediyl)bis-(6-(1-naphthyl)-5-cyano-4-oxopyrimidine) (30i). Yield 
92%; 1H NMR (CD3OD) δ 4.37 (s, 4H), 7.32 (s, 4H), 7.44-7.57 (m, 8H), 7.74 (d, 2H, J = 8.0 Hz), 7.91 (d, 
2H, J = 8.2 Hz), 7.96 (dd, 2H, J = 2.0 Hz, 7.0 Hz); 13C NMR (CD3OD) δ 35.7, 94.1, 119.1, 126.2, 126.5, 
127.4, 127.8, 127.9, 129.5, 130.3, 130.9, 132.0, 135.2, 136.6, 138.5, 171.6, 174.0, 175.0.  HRMS-ESI (-): 
Calc. for C38H23N6O2S2: 659.1324. Found: 659.1343 [M-H]-. 
General procedure for the preparation of S-benzyl-2-thiouracils (31d, e, g-i). To a solution of 
the 2-thiouracil derivatives (24d, e, g-i, 2 mmol) and benzylchloride (253 mg, 2 mmol) in acetonitrile (10 
mL) was added K2CO3 (829 mg, 6 mmol). The mixture was heated under reflux for 8 h and then cooled to 
room temperature. The liquid was removed on a rotavapor, and the residue was washed by H2O (20 mL). 
Then the solid was dried in a vacuum oven at 40 ºC overnight to give 31d, e, g-i. 
S-Benzyl-5-cyano-6-(4-ethylphenyl)-2-thiouracil (31d). Yield 28%; 1H NMR (DMSO-d6) δ 
1.27 (t, 3H, J = 7.6 Hz), 2.71 (q, 2H, J = 7.6 Hz), 4.40 (s, 2H), 7.21 (m, 1H), 7.28 (m, 4H), 7.41 (d, 2H, J 
= 7.2 Hz), 7.74(d, 2H, J = 8.4 Hz); 13C NMR (DMSO-d6) δ 16.0, 29.8, 36.0, 90.6, 120.1, 128, 128.8, 
129.2, 129.4, 129.8, 130.1, 136.0, 139.8, 148.2, 170.2, 174.9. HRMS-ESI (+): Calc. for C20H18N3OS: 
348.1171. Found: 348.1185 [M+H]+. 
S-Benzyl-5-cyano-6-(4-isopropylphenyl)-2-thiouracil (31e). Yield 40%; 1H NMR (DMSO-d6) δ 
1.23 (d, 6H, J = 6.8 Hz), 2.94 (septet, 1H, J = 6.8 Hz), 4.30 (s, 2H), 7.22 (t, 1H, J = 6.8 Hz), 7.31 (m, 4H), 
7.40 (d, 2H, J = 7.2 Hz), 7.73 (d, 2H, J = 7.6 Hz); 13C NMR (DMSO-d6) δ 23.7, 33.3, 33.8, 88.7, 120.3, 
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126.0, 126.7, 128.2, 128.3, 128.8, 135.3, 139.0, 150.2, 166.8, 170.5, 171.5. HRMS-ESI (+): Calc. for 
C21H20N3OS: 362.1327. Found: 362.1335 [M+H]+. 
S-Benzyl-5-cyano-6-(4-bromophenyl)-2-thiouracil (31g). Yield 33%; 1H NMR (DMSO-d6) δ 
4.27 (s, 2H), 7.22 (t, 1H, J = 7.2 Hz), 7.29 (t, 2H, J = 7.2 Hz), 7.39 (d, 2H, J = 7.2 Hz), 7.67 (d, 2H, J = 
8.4 Hz), 7.71 (d, 2H, J = 8.4 Hz); 13C NMR (DMSO-d6) δ 33.8, 88.9,120.0, 123.2, 126.7, 128.3, 128.9, 
130.2, 131.1, 136.9, 139.0 165.8, 170.1, 171.8. HRMS-ESI (+): Calc. for C18H13N3OSBr: 397.9963. 
Found: 397.9950 [M+H]+. 
S-Benzyl-5-cyano-6-(biphenyl-4-yl)-2-thiouracil (31h). Yield 37%; 1H NMR (DMSO-d6) δ 
4.32 (s, 2H), 7.23 (t, 1H, J = 7.6 Hz), 7.31 (t, 2H, J = 7.6 Hz), 7.40 (m, 3H), 7.50 (t, 2H, J = 7.6 Hz), 7.74 
(d, 2H, J = 8.0 Hz), 7.77 (d, 2H, J = 8.4 Hz), 7.90 (d, 2H, J = 8.0 Hz); 13C NMR (DMSO-d6) δ 33.8, 89.1, 
126.4, 126.8, 126.8, 127.9, 128.3, 128.8, 128.9, 129.0, 136.6, 139.0, 139.4, 141.4, 166.4, 169.7, 171.3. 
HRMS-ESI (+): Calc. for C24H18N3OS: 396.1171. Found: 396.1187 [M+H]+. 
S-Benzyl-5-cyano-6-(1-naphthyl)-2-thiouracil (31i). Yield 43%; 1H NMR (DMSO-d6) δ 4.26 (s, 
2H), 7.23 (t, 1H, J = 7.2 Hz), 7.29 (t, 2H, J = 7.2 Hz), 7.39 (d, 2H, J = 7.2 Hz), 7.55 (m, 5H), 7.78 (d, 1H, 
J = 8.0 Hz), 7.99 (t, 2H, J = 6.8 Hz); 13C NMR (DMSO-d6) δ 33.8, 92.4, 119.3, 125.2, 125.4, 126.0, 126.2, 
126.4, 126.8, 128.2, 128.3, 128.9, 130.1, 133.1, 135.9, 138.9, 168.7, 167.6, 171.4. HRMS-ESI (+): Calc. 
for C22H16N3OS: 370.1014. Found: 370.1015 [M+H]+. 
1.3.2 Biological evaluation 
General in vitro biological methods: EcN68, the N-terminal fragment of SecA from E. coli 
without the C-terminal regulatory domain, and EcSecA, the full length SecA from E. coli,  were over-
expressed from pIMBB-8108 and pT7-SecA,109 respectively, and purified as described.110,111 EcN68 was 
used for screening because it has higher intrinsic activity and is more sensitive to inhibitors. 
All potential inhibitors were dissolved in 100% DMSO. The ATPase activity was determined by 
the release of phosphate (Pi) detected by malachite green as described14 in a modified procedure102 and in 
the presence of 10% DMSO. Inhibitory effect was determined by the percentage of the remaining ATPase 
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activity as compare to the controls without test compounds. Briefly, 50 µL reaction mixture was prepared 
so that it contained 2.25 µg N68 or 5 µg SecA, 2 mM ATP, 50 mM Tris-HCl (pH7.6), 20 mM KCl, 20 
mM NH4Cl, 1 mM DTT, and 2 mM Mg(OAc)2. Reactions took place at 40 °C for 20 min (for N68) or 40 
min (for SecA) then were stopped by adding 800 µL of malachite green and then 100 µL of 34% citric 
acid within 1 min. The mixtures were incubated at room temperature for 40 min and then the absorption 
at 660 nm was measured. All assays were done at least in triplicate, and the results were presented as bar 
graphs with standard error of the mean. 
General in vivo biological methods: Log-phase growing cells (O.D. 600nm~ 0.5 to 1.0) were 
diluted to an absorbance of 0.05 at O.D. 600 nm, added with indicated compounds, and followed by 
culturing in an Eppendorf Thermomixer R (Brinkmann instruments, Inc.) at 37 °C,1050 rpm for 10 to 12 
hours.  All cultures contain 5% DMSO with a final volume of 100 µl. All tested compounds were 
dissolved in 100% DMSO (Sigma). 
Bacterial strain: NR698 (MC4100 imp4213)112 with increased outer membrane permeability. 
MC4100, an Ecoli K-12 wild-type strain.113 
1.3.3 Computational analysis 
Molecular simulation of ligand-SecA complexes. The 3D structures for these compounds were 
refined using the PM3 method in the MOPAC 7 program114 and assigned with AM1-BCC partial 
charges115-117 by the QuACPAC program. All partial charges on the atoms of the homology model were 
derived from AMBER 8 parameters. Docking of the ligands into SecA around the active site (included 
residues Gly80, Mse81, Arg82, His83, Phe84, Gln87, Arg103, Thr104, Gly105, Glu106, Gly107, Lys108, 
Thr109, Leu110, Arg138, Asp209, Glu210, Arg509 and Gln578) was performed by using DOCK 5.4..118 
After docking, MD simulations were conducted with the ligand-receptor complexes following similar 
procedures we reported before. 104-107 In brief, the docked complexes were solvated by using the TIP3P 
water model,119 subjected to 500-steps of molecular mechanics minimization and molecular dynamics 
simulations at 300 K for 1.0 ns using the SANDER module in the AMBER 8 program.120 The resulting 
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structures were then analyzed using PyMOL 1.0,121 HBPLUS 3.06122 and Ligplot 4.22123 to identify spe-
specific contacts between ligands and SecA. During the computation, molecular docking (DOCK 5.4), 
binding analysis (HBPLUS 3.06 and Ligplot 4.22) and visualization (PyMOL 1.0) were carried out on a 
Xeon-based Linux workstation. Molecular mechanics calculations and molecular dynamics simulations 
(AMBER 8) were performed on URSA, a 160-processor computer based on the Power5+ processor and 
IBM’s P series architecture. 
1.4 Conclusion 
Through optimization of two hit compounds 8 (SEW-05929) and 9 (HTS-12302) identified from 
virtual screening and 12 identified from random screening, we have found a series of thiouracil 
derivatives that are much more potent than the primary hits. The two most potent compounds, 30g and 
30h, are 50-fold more active than the hit compounds. Results of antimicrobial tests suggest that future 
work should focus on low molecular weight analogs of 31h for in vivo applications. These compounds are 
the first in its class and should be very useful as research tools in studying bacterial protein transport. The 
new inhibitory structural features identified should also be very useful for further structural optimization 
in search of even more potent inhibitors as potential antimicrobial agents. 
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2 MECHANISTIC STUDIES OF 1,2,4,5-TETRAZINE CLICK CHEMISTRY AND ITS 
APPLICATION IN DNA POSTSYNTHETIC FUNCTIONALIZATION 
Abstract: This chapter is mainly based on my publications: Chem. Commun. in 2012, from page 
1736-1738. Post synthetic modification is an important and efficient way of DNA functionalization 
especially in DNA aptamer selection. In this research, the feasibility of norbornene (Neo) modified 
thymidine triphosphate incorporation was described. Besides, substituted tetrazines have been found to 
undergo facile inversed electron demand Diels-Alder reactions with “tunable” reaction rates. This finding 
paves the way to utilize tetrazine conjugation reactions for not only DNA but also other labeling work. 
2.1 Introduction 
DNA molecule is not only served as genomic material but also has structural purpose which is 
used in nanosensing,124 nanocomputing,125 aptamer selection,126-128 and reaction encoding.129,130 Among 
these applications, aptamer selection is one of our lab’s long term interests. DNA aptamer is a DNA 
molecule that forms a certain 3-D structure, which could bind to specific targets with high affinity (Kd in 
the nanomolar to micromolar range). These targets include small molecule, protein and even cell. Finding 
an aptamer is normally achieved through in vitro selection process termed SELEX (Systematic Evolution 
of Ligands by Exponential Enrichment). Typically in this process, DNA single strands from the 
combinatorial library bind with the target are enriched and separated from the unbinding or weak binding 
strands, which are subjected to polymerase chain reaction (PCR) and next round of selection.  
Glycans, complex sugar chains and the important role of protein glycosylation, have been 
drawing tremendous amount of attentions nowadays. Proteins on cell surface are usually heavily 
glycosylated, which indicating the importance of these post-translational modifications in cell signaling, 
cell-cell interactions and the immune response, for instance.131 Altered protein glycosylation patterns are 
implicated in a number of diseases such as diabetes132 and cancer.133,134 Besides, glycan biomarkers have 
been identified from many other diseases.135-138 However, as a post-translational process, glycosylation is 
by definition nontemplated, in other word, glycans on glycoproteins are indirect gene products. Besides, 
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unlike phosphorylation, tens to hundreds of different glycan attachments can be found on one protein 
makes probing and differentiation exponentially more difficult.  
As mentioned above, high affinity and specificity make aptamers possible tools for studying 
glycosylation and diagnose and therapy of glycosylation-related diseases. Boronic acid is well-known by 
its strong interactions with diols,139-157 alcohols, and nucleophiles (Scheme 2.1).158,159 Therefore, 
considering the intrinsic affinity of boronic acid to carbohydrates, incorporation of the boronic acid 
moiety into DNA could lead the discovery of new aptamers160-162 against carbohydrates, glycoproteins, 
and glycolipids. Furthermore, boronic acid modified DNA aptamer would differentiate the glycosylation 
patterns.  
 
Scheme 2.1. Illustration of boronic acid-diol interaction 
Based on the hypothesis that boronic acid modified DNA would have enhanced recognition of 
carbohydrate, our group has previously reported the design and synthesis of boronic acid modified 
thymidine analogues. For example, first generation boronic acid modified thymidine triphosphate (B-TTP 
36a-c Figure 2.1),163,164 which was incorporated into DNA through PCR, demonstrated the feasibility of 
boronic acid modified DNA aptamer selection for glycoprotein.165 The second generation boronic acid 
modified TTP that changes fluorescent properties upon binding to sugar allows incorporated DNA to 
sense target without any additional reporting groups.166 As we reported earlier, B-TTP with a 
naphthalimide moiety, named as NB-TTP (36d Figure 2.1),167 has also been successfully synthesized and 
introduced
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reactions and reagents that allow for facile and specific reactions. Many reagents have been identified that 
serve this purpose very well in different situations. These include difluorinated cyclooctyne (DIFO),186 
dibenzocyclooxtyne (DIBO),177,187 aza-dibenzocyclooctyne  (DIBAC),188 and biarylazacyclooctynone 
(BARAC).189 We then took advantage of DIFO click tool and converted it to the phosphoramidite 
building block for DNA post-synthetic BA modifications. 
 
Scheme 2.2. Solid-phase synthesis of boronic acid modified DNA through copper-free post-synthesis 
modification 
As showed in Scheme 2.2, phosphoramidite 37 was used in solid phase synthesis, which gave a 
“handle” to DNA molecule 38. This handle was later clicked with BA 39 to obtain modified DNA 
product 40.190 This was the first demonstration that BA can be successfully introduced into DNA through 
post-synthesis. Nevertheless, all these approaches used one type of reactions: 1,3-dipolar cycloaddition 
involving an azido and an alkynyl group. However, this field needs more such reactions in its arsenal for 
reasons of multiplexing, labeling diversity, biocompatibility under different conditions, and compatibility 
with other functional groups as well reaction conditions for reagent preparation. In addition, rate 
difference among various click reactions can also be exploited for selective labeling.191 Last but not the 
least, due to lack of symmetry, multiple regioisomers were generated (40a and 40b Scheme 2.2). Thus 
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having click reactions with sufficiently different reaction rates and single isomer product will be very use-
useful in DNA post-synthetic modification.  
Fox187,192,193 and Weissleder178  have developed a reaction using tetrazine and a strained trans-
alkene. The reaction is very fast with a second order rate constant of 2000 to 22000 M-1s-1, making it very 
useful for biolabeling applications. However, the asymmetric reaction product makes it hard to be used in 
DNA aptamer selection work where single isomer modification productivity is required. Recently, 
Jäschke reported a bioorthogonal pair, tetrazine-norbornene (Figure 2.2), which is successfully utilized in 
solid phase synthesis of modified DNA for post-synthesis.194 This first example intrigued us, and 
therefore we used this in our enzymatic approach to prepare DNA molecule with a handle for later 
manipulations. However slow reaction rates along with asymmetric productivity made the tetrazine-
norbornene pair unacceptable in BA modified DNA aptamer selection. 
 
Figure 2.2. Illustration of Solid-phase synthesis of modified DNA through copper-free post-synthesis 
modification involving inverse-electron demand Diels-Alder reaction 
In our DNA labeling work,167,195,196 we are interested in developing fast click reactions with 
tunable reaction rates and sympatric product that can be easily obtained. We thus turned to another type of 
inverse-electron demand Diels-Alder reactions (IEDDA) involving an alkyne and tetrazine for several 
reasons. First, Schuster197 has demonstrated that un-substituted tetrazine can react very quickly with 
alkenes and alkynes. Second, many strained alkynes have been reported, giving us a set of “tools” for the 
intended studies. Third, unlike azido compounds, tetrazine’s reactivity can be tuned by manipulating its 
electron deficiency through the introduction of functional groups at the 3,6-position.  In our case, we need 
reactions to be fast enough so that at 10 µM concentrations, the half-life is no more than 2 h.  This 
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requires the second order rate constant to be higher than 20 M-1 s-1 at ambient temperature. This rate is 
higher than that of most strained promoted azido-alkyne cycloadditions (SPAAC) reported thus far.  
The reaction between un-substituted tetrazine and cyclooctyne has been reported with a stated 
second order rate constant of 27.1 M-1s-1. However the highly volatile 1,2,4,5-tetrazine is not suitable for 
any labeling work.197 In our initial studies, we found the second order rate constant for the reaction 
between cyclooctyne (50) and diphenyltetrazine (51) to be 0.07 M-1s-1 (Figure 2.5). This rate is similar to 
that of a typical SPAAC reaction180 and is slower than what we need. Thus, we undertook the effort to 
explore ways to enhance the reaction rates by performing modifications guided by computational work. In 
the present research, synthesis of norbornene modified TTP analog (Neo-TTP 48, Scheme 2.3), enzymatic 
incorporation the Neo-TTP into DNA, post-synthetic modification, and a new click reaction with tunable 
reaction rates are reported. 
2.2 Results and discussions 
2.2.1 Synthesis of Norbornene-modified deoxyuridine (Neo-TTP) 
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Neo-TTP (48) was prepared in only 4 steps. Firstly, we followed literature to get compound 47 in 
3 steps.194,198 Then the triphosphorylation was accomplished by the classical one-pot three-step method199 
(Scheme 2.3) to provide Neo-TTP (48) in 9% overall isolated yield, which was then used for enzymatic 
incorporation. 
2.2.2 Enzymatic incorporation and post-synthesis labeling of Neo-TTP 
 
Figure 2.3. Enzymatic incorporation and post-synthesis labeling of Neo-TTP 48 with 49 
The incorporation of Neo-TTP into DNA was studied through primer extension. Specifically, the 
excrement was conducted by using a short sequence of 21-mer oligonucleotide 5’-
GGTTCCACCAGCAACCCGCTA-3’ as the template, a 14-mer oligonucleotide 5’-
TAGCGGGTTGCTGG-3’ as the primer, Neo-TTP as the TTP analog and the Klenow fragment as the 
enzyme (Figure 2.3). This type of experiment has been successfully used in our previous incorporation 
studies of different functionalized DNA.163,164,200 Klenow fragment without 3’-5’ exo-nuclease activity 
was used to avoid cleavage of the template. Since the primer was designed in such a way that the first 
elongated nucleotide would be a thymidine triphosphate, there are two possible scenarios in the 
experiment: either full extension or no extension at all. In order to study the DNA products 
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Figure 2.5. Strain-promoted [4+2] cycloadditions of 1,2,4,5-tetrazine 51 and cyclooctynes 53.  
Tetrazine: 1 mM, Alkyne: 10 mM in dried MeOH 
The reaction between cyclooctyne (50) and a substituted tetrazine (51) leads to significant 
changes in the UV-vis spectrum of tetrazine due to its conversion to a 1,2-diazine product (Figure 2.5).  
Hence, reaction can be easily monitored. We first studied the reaction between cyclooctyne (50) and 3,6-
diphenyl-1,2,4,5-tetrazine (51) in dry methanol as a reference. The rate constant for the reaction between 
diphenyltetrazine and cyclooctyne was found to be 0.07 M-1s-1 (Table 2.1), which is far smaller than that 
of the reaction between un-substituted tetrazine and cyclooctyne. Since the reaction between 1,2,4,5-
tetrazines and an octyne depends on the LUMOdiene-HOMOphil gap,201-203 we were interested in exploring 
ways to lower the LUMO of the diene or elevate the HOMO of the dienophile in order to facilitate the 
reaction. In such a case, it is reasonable to expect that electron donating substituents, as well as high strain 
energy will increase the HOMO energy of the dienophiles, and electron withdrawing substituents will 
decrease the LUMO energy of the diene, leading to a decrease in the LUMOdiene-HOMOphil gap and 
consequently an increase in the reaction rate. 
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2.0±0.3 M-1s-1 44.8±4.9 M-1s-1 
ND 40.9±13.8 M-1s-1 
Table 2.1. Second order rate constants of cyclooctynes with tetrazines. 
We then conducted quantum mechanics (QM) calculation using known strained alkynes and 
trans-cyclooctene and some modified tetrazines. From Figure 2.6, one can see that relative to cyclooctyne 
(51), the HOMO of BCN204 (53) is 1.5 kcal/mol higher, giving this a chance to have increased reactivity. 
Installing electron withdrawing groups on cyclooctynes decreases the HOMO energy substantially. For 
example, computational results indicate that the HOMO energy decreases by 6.1 kcal/mol for DIFO186 (58) 
and 11.5 kcal/mol for fluorocyclooctyne205 (59) relative to cyclooctyne. Correspondingly, di-pyridine 
substituted 1,2,4,5-tetrazine 55 lowers the LUMO energy by 2.3 kcal/mol relative to 3,6-diphenyl-1,2,4,5-
tetrazine 51 (Figure 2.6). Such calculations suggest that the BCN-tetrazine (55) pair could have 
significantly improved reactivity.  
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Figure 2.6. Orbital energy of cyclooctynes and tetrazines 
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Indeed, when we tested the reactivity of diphenyltetrazine (51) with 53 at a 1:10 ratio (tetrazine: 1 
mM; alkyne: 10 mM), the reaction finished within 10 minutes, with a second order rate constant of 3.3 M-
1s-1 (Figure 2.5). This represents a 47-fold improvement in reaction rate compared to the reaction between 
cyclooctyne and diphenyltetrazine. To further accelerate the reaction, two electron-withdrawing groups 
were attached to the tetrazine ring to give 55. The second order rate constant for the reaction between 3,6-
di-2-pyridyl-1,2,4,5-tetrazine (55) and alkyne (53) in dry MeOH at ambient temperature was found to be 
44.8 M-1s-1, which  represents a 640-fold improvement in reaction rate over the tetrazine-cycloctyne pair. 
On the other hand, 58 and 59 did not react with tetrazine 55 to an appreciable degree, as expected. To 
achieve a deeper understanding of the improved reaction rates, Density Functional Theory (DFT) 
calculations at the 6-31G** level of theory were performed to examine the possible transition state(s) and 
activation energies. Schematic representation of the energy profiles for the tetrazine alkyne reactions are 
shown in Figure 2.7. All of the QM energies are in kcal/mol and are relative to the reactants (50 and 51 at 
the top of Figure 2.7, and 53 and 51 at the bottom of Figure 2.7). The activation energy for the first step of 
the IEDDA reaction between 51 and 53 via transition state TS1’ is 17.6 kcal/mol as compared to 23.3 
kcal/mol for the reaction between cyclooctyne 50 and tetrazine 51. The computational results support the 
idea that the increase HOMO energy in BCN (53) compared with cyclooctyne (50) translates into lowered 
activation energy and thus increased reaction rate. The intermediate IN1 from the first step of the 50-51 
reaction pair quickly loses nitrogen gas to yield product 52 by passing through a low activation barrier of 
8.6 kcal/mol, with the reaction being strongly exergonic by -91.4 kcal/mol. Because of the low barrier for 
the second step, the reaction rate is entirely controlled by the first step of the reaction. For the reaction 
between BCN (53) and tetrazine 51, the situation is similar except that the conversion of the intermediate 
IN1’ to the final product has almost no activation barrier, with the overall reaction being strongly 
exergonic by -88.1 kcal/mol. All these results indicate that the IEDDA reaction and the subsequent 
elimination reaction take place spontaneously and irreversibly toward the pyridazine products.  
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Figure 2.7. Schematic representations (energy vs. reaction coordinate) of the reaction between diphenyl 
tetrazine and strained alkynes. 
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With these exciting findings and resulting tunable reaction rates, we turned our attention to 
developing the chemistry needed for bioconjugation. In order to do so, a “handle” need to be installed on 
the tetrazine system. Therefore 4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzoic acid206 was prepared. 
As a model, isopropyl amine was chosen for conjugation with the benzoyl chloride tetrazine derivative. 
The reaction between isopropyl amide tetrazine 56 and 53 gave a second order rate constant of 40.9 M-1s-1, 
with half-lives of 24 seconds and 0.68 hour at mM and 10 μM concentrations, respectively. This is among 
the fastest click reactions, and can be used for a variety of labeling work. 
2.3 Conclusion 
In summary, norbornene modified TTP was successfully synthesized and incorporated into DNA 
through enzymatic primer extension. However slow reaction rate is not acceptable for DNA aptamer 
selection process. Therefore a new inverse electron-demand Diels-Alder reaction involving 1,2,4,5-
tetrazine and cyclooctynes with tuned reaction rate was developed. The facile conjugation was also 
demonstrated. The reaction rates found are among the fastest involving a tetrazine and alkyne. 
Furthermore, the wide range of reaction rates (over 64-fold difference) that can be achieved suggest 
possibilities of using such chemistry for mutiplexing click labeling. This work paves the way to utilize 
BCN-tetrazine conjugation reactions for not only DNA but also other labeling work. 
2.4 Experimental part 
2.4.1 Synthesis 
Materials and Methods. All reagents and solvents were reagent grade or were purified by 
standard methods before use. Column chromatography was carried out on flash silica gel 
(Sorbent 230–400 mesh). TLC analysis was conducted on silica gel plates (Sorbent Silica G 
UV254). NMR spectra were recorded at 1H (400 MHz) and 13C (100 MHz) on a Bruker 
instrument. Chemical shifts (δ values) and coupling constants (J values) are given in ppm and 
hertz, respectively, using solvents (1H NMR, 13C NMR) as the internal standard. DIFO (58),186 
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methyl 1-fluorocyclooct-2-ynecarboxylate (59),205 compound 50,3 compound 51,5 compound 
53,4 and compound 556 were synthesized according to literature procedures. 
Preparation of Neo-TTP 
 
Preparation of Cyclooctyne 50.207 
 
Scheme 2.4. Reagents and conditions for the synthesis of cyclooctyne 50 
Cyclooctyne (50): 1H NMR (CDCl3) δ 2.14 (s, 4H), 1.83 (s, 4H), 1.60 (s, 4H). 13C NMR 
(CDCl3) δ 94.6, 34.6, 29.8, 21.0. 
Preparation of (1R,8S,9S)-Bicyclo[6.1.0]non-4-yn-9-ylmethanol (endo-53).204  
 
Scheme 2.5. Reagents and conditions for the synthesis of (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethanol 
(endo-53) 
(1R,8S,9S)-Bicyclo[6.1.0]non-4-yn-9-ylmethanol (endo-53): 1H NMR (CDCl3): δ 3.66 
(d, J = 8.0 Hz, 2H), 2.28-2.14 (m, 6H), 1.55-1.54 (m, 2H), 1.31-1.25 (m, 1H), 0.89-0.85 (m, 2H). 
13C NMR (CDCl3) δ 98.9, 59.7, 29.0, 21.5, 21.3, 20.0. 
Preparation of 3,6-diphenyl-1,2,4,5-tetrazine 51.208 
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Scheme 2.6. Reagents and conditions for the synthesis of 3,6-diphenyl-1,2,4,5-tetrazine 51. 
3,6-Diphenyl-1,2,4,5-tetrazine (51): 1H NMR (CDCl3): δ 8.65 (t, J = 6.0 Hz, 4H), 7.65-
7.59 (m, 6H),. 13C NMR (CDCl3) δ 164.0, 132.7, 131.8, 129.3, 128.0. 
Preparation of 3,6-di(pyridin-2-yl)-1,2,4,5-tetrazine 55.209 
 
Scheme 2.7. Reagents and conditions for synthesis of 3,6-di(pyridin-2-yl)-1,2,4,5-tetrazine 55 
3,6-Di(pyridin-2-yl)-1,2,4,5-tetrazine (55): 1H NMR (CDCl3): δ 8.99 (d, J = 4.8 Hz, 2H), 8.76 
(d, J = 8 Hz, 6H), 8.04-7.99 (m, 2H), 7.60-7.57 (m, 2H). 13C NMR (CDCl3) δ 163.8, 151.0, 150.0, 
137.4, 126.5, 124.5. 
Preparation of N-isopropyl-4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin3-yl) benzamide 
56.210 
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Scheme 2.8. Reagents and conditions for the synthesis of N-isopropyl-4-(6-(pyrimidin-2-yl)-1,2,4,5-
tetrazin-3-yl)benzamide 56 
4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzoic acid (74)7: To a solution of 2-
pyrimidinecarbonitrile (935 mg, 8.9 mmol) in 30 mL ethanol, 4-cyanobenzoic acid (1.96 g 13.3 
mmol) was added, followed by addition of hydrazine monohydrate (5.5 mL). Then the solution 
was heated under reflux for 20 h with stirring. After cooling to r.t., the solid was collected by 
filtration and washed with acetone (2  50 mL). The dihydrotetrazine without carboxyl group (71) 
went into acetone. The remaining solid was added acetic acid (10mL) followed by an aqueous 
solution of NaNO2 (2.76g, 40 mmol) at 10 °C. The purple colored tetrazine was collected and 
washed with water (3  10 mL). The solid was added into nearly boiled DMF and kept at this 
temperature for another 5 min. The DMF solution was filtered while it was hot. The filtrate, 
which contained mono-carboxyl substituted product, was collected and dried under vacuum to 
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give a purple product (300 mg, 12%). The benzoic acid tetrazine was used for next step without 
further purification. 
N-Isopropyl-4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzamide (56): To a 
suspension of 4-(6-(pyrimidin-2-yl)-1,2,4,5-tetrazin-3-yl)benzoic acid (74, 60 mg, 0.214 mmol) 
in 5 mL DCM, thionyl chloride (187 µL, 257 mmol) was added. This mixture was refluxed for 
20 h with stirring, at which point TLC indicated completion of the reaction. The solution was 
cooled to r.t. and dried under vacuum. The residue was suspended in dry 3 mL DCM, then 
propan-2-amine (55 µL, 0.64 mmol) was added and the resulting mixture was stirred at r.t. for 4 
h. DCM was removed in vacuum and the reaction mixture was purified by silica gel column 
chromatography (DCM: MeOH, 20:1) to give a purple solid product (40 mg, 59 %). 1H NMR 
(CDCl3): δ 9.14 (d, J = 2.0 Hz, 2H, 4-Pyr-H, 6-Pyr-H), 8.78 (d, J = 4.0 Hz, 2H, 2’-Ph-H, 6’-H), 
8.00 (d, J = 4.0 Hz, 2H, 3’-Ph-H, 5’-Ph-H), 7.60 (br, 1H, 5-Pyr-H), 6.17 (d, J = 4.0 Hz, 1H, -NH), 
4.34-4.32 (m, 1H, -CH-NH-), 1.32 (s, 3H, -CH3), 1.31 (s, 3H, -CH3); 13C NMR (CDCl3) δ 165.7, 
164.0, 163.1, 159.4, 158.4, 139.2, 133.7, 128.9, 127.8, 122.6, 42.2, 22.8. MS calcd. For 
C16H15N7O [M+H]+ 322.1, found 322.3 
2.4.2 Enzymatic incorporation and post-synthesis labeling 
2.4.2.1 General procedure for Klenow fragment primer extension using dTTP or Neo-TTP 
The reaction mixtures of a final volume of 50 μL contained 21-mer template (5’- 
GGTTCCACCAG-CAACCCGCTA-3’, 20 μM), 14-mer primer (5’-TAGCGGGTTGCTGG-3’, 20 μM), 
10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, 1 mM Dithiothreitol at pH 7.9, dATP, dCTP, dGTP, 
dTTP or Neo-TTP at concentrations of 200 μM and 0.5 U μL-1 Klenow fragment. The prepared reaction 
solution was incubated at 25 °C for 30 min. The primer extension products were analyzed by 20% PAGE. 
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2.4.2.2 Post-synthesis labeling of the primer extension products Neo-DNA 
The primer extension product was purified using Millipore Amicon 3 kDa spin column and react 
with 30 μL of 2 mM 49 in 1 × PBS buffer. The reaction was allowed to stand at 37 °C for 1 h, 2h, 4h and 
overnight. The negative control experiment was performed following the same procedure. The resulting 
post-synthetic modified DNA products were purified with Millipore Amicon 3 kDa spin column and 
analyzed by 20% PAGE. 
2.4.3 Characterization of cyclization products 
General procedure for strain-promoted inverse electron demand Diels-Alder 
reactions with 1,2,4,5-tetrazine.  
To a solution of tetrazine (51, 55, 56) in CH2Cl2 (1 mL), alkyne (50, 53) in CH2Cl2 (1 mL) 
was added. Reactions were stirred at room temperature for 5 to 30 min. The progress of the 
reaction was monitored by TLC. Upon completion, the reaction mixture was directly loaded on 
the flash column chromatography for purification. 
Compound 52 
Purified by eluting with DCM:MeOH (10:1, Rf = 0.65) (white solid, 91%). 
1H NMR (CDCl3) δ 7.55-7.47 (m, 10H, Ph-H), 2.83-2.82 (m, 4H, -CH2-C=C-), 1.60 (br, 4H, -
CH2-), 1.43 (br, 4H, -CH2-). 13C NMR (CDCl3) δ 161.1, 139.0, 138.2, 129.1, 128.3, 128.2, 30.3, 
27.1, 25.9. MS calcd. For C22H22N2 [M+H]+ 315.2, found 315.3 
Compound 54 
Purified by eluting DCM:MeOH (10:1, Rf = 0.55) (white solid 
88%). 1H NMR (CDCl3) δ 7.48-7.41 (m, 10H, Ph-H), 3.63 (d, J = 3.6 Hz, 
2H, -CH2-OH), 2.93-2.85 (m, 2H, -CH2-C=C-), 2.75 (br, 2H, -CH2-C=C-), 
NN
OH
H H
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2.50 (br, 1H, -CH-CH2OH), 2.18-2.15 (br, 2H, -C-CH-C-), 1.43-1.42 (br, 2H, -CH2-), 1.13 (br, 
2H, -CH2-) 13C NMR (CDCl3) δ 160.8, 140.5, 137.9, 129.2, 128.4, 128.2, 58.8, 28.2, 24.3, 22.9, 
20.4. MS calcd. For C26H23NO3 [M+H]+ 357.2, found 357.3. 
Compound 76 
Purified by eluting DCM:MeOH (10:1, Rf = 0.54) (white solid 
90%). 1H NMR (CDCl3) δ 8.66 (d, J = 2.2 Hz, 2H, 6-Py-H), 7.84-7.79 (m, 
4H, 3-Py-H, 4-Py-H), 7.33-7.30 (m, 2H, 5-Py-H), 3.01-2.98 (m, 4H, -CH2-
C=C-), 1.72 (br, 4H, -CH2-), 1.38 (br, 4H,  -CH2-). 13C NMR (CDCl3) δ 158.7, 156.9, 148.4, 
140.9, 136.6, 124.8, 123.1, 30.3, 26.4, 25.9. MS calcd. For C20H20N4 [M+H]+ 317.2, found 317.2 
Compound 77 
Purified by eluting DCM:MeOH (10:1, Rf = 0.35) (white solid 
89%). 1H NMR (CDCl3) δ 8.72 (d, J = 2.0 Hz, 2H, 6-Py-H), 7.95-7.85 (m, 
4H, 3-Py-H, 4-Py-H), 7.39-7.36 (m, 2H, 5-Py-H), 3.72 (d, J = 3.6 Hz, 2H, -
CH2-C-OH), 3.06-3.05 (m, 4H, -CH2-C=C-), 2.39-2.36 (br, 2H, -CH2-), 
1.62 (br, 2H, -CH2-), 1.10 (br, 3H, -CH-, -CH2-). 13C NMR (CDCl3) δ 159.1, 157.0, 148.7, 142.2, 
136.8, 125.0, 123.3, 59.5, 27.8, 24.4, 22.7, 19.7. MS calcd. For C22H22N4O [M+H]+ 359.2, found 
359.3. 
Compound 78 
Purified by eluting DCM:MeOH (10:1, Rf = 0.32) (white 
solid 82%). 1H NMR (CDCl3) δ 8.94 (d, J = 2.4 Hz, 2H, 4-Pyr-H, 6-
Pyr-H) 7.86 (d, J = 4.2 Hz, 2H, 2’-Ph-H, 6’-Ph-H), 7.53 (d, J = 4.0 
Hz, 2H, 3’-Ph-H, 5’-Ph-H), 7.42 (t, J = 5.0 Hz, 1H, 5-Pyr-H), 6.25 
(d, J=3.8 Hz, 1H, -NH), 4.35-4.26 (m, 1H, -NH-CH-), 3.72 (d, J = 3.6 Hz, 2H, -CH2-C-OH), 
NNNN
OH
H H
NNN
N
OH
O
HN
H H
N N N N
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2.99-2.89 (m, 2H, -CH2-C=C-), 2.83-2.78 (m, 2H, -CH2-C=C-), 2.32-2.31 (br, 1H, -CH-), 2.19-
2.17 (br, 1H, -CH-), 1.84 (br, 1H, -CH-), 1.59-1.56 (br, 2H, -CH2-), 1.29 (s, 3H, -CH3), 1.27 (s, 
3H, -CH3), 1.15 (br, 2H, -CH2-). 13C NMR (CDCl3) δ 166.4, 164.8, 161.0, 158.0, 157.2, 141.2, 
141.0, 140.5, 135.2, 129.4, 127.0, 120.4, 59.2, 42.0, 28.0, 24.1, 22.8, 21.0, 19.7, MS calcd. For 
C26H29N5O2 [M+H]+ 444.2, found 444.3. 
2.4.4 Kinetics measurements of 51, 55 and 56 with 50 or 53. 
UV/Vis kinetic measurements: Separate solutions of pure tetrazines 51, 55, 56 and pure 
alkynes 50, 53 (>95-98% by 1H-NMR) were prepared in HPLC-grade MeOH at 297 K. The 
stability of 51, 55, and 56 in MeOH was examined by monitoring its absorption maximum at 295 
nm. Solutions containing 51, 55, 56 (25 uM) and 10-18 fold excess of an alkyne (50 or 53) were 
pipetted into quartz cuvettes for UV measurements and thoroughly mixed. All kinetic runs were 
triple triplicates. Curve fitting was operated in Prism3 software. 
A) Tetrazine 51 with alkyne 50 
 
Figure 2.8. Reaction rate between Ph-tetrazine 51(25 uM) and alkyne 50(450 uM). 
B) Tetrazine 55 with alkyne 50 
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Figure 2.9. Reaction rate between Py-tetrazine 55(25 uM) and alkyne 50(250 uM, 300 uM, 350 uM, 400 uM, 
450 uM). 
Second order rate constant k2= 2.0 ± 0.3 M-1s-1 
C) Tetrazine 51 with alkyne 53 
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Figure 2.10. Reaction rate between Ph-tetrazine 51(25 uM) and alkyne 53(250 uM, 300 uM, 350 uM, 400 uM, 
450 uM). 
Second order rate constant k2= 3.3 ± 0.4 M-1s-1 
 
D) Tetrazine 55 with alkyne 53 
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Figure 2.11. Reaction rate between Py-tetrazine 55(25 uM) and alkyne 53(250 uM, 300 uM, 350 uM, 400 uM, 
450 uM). 
Second order rate constant k2= 44.8 ± 4.9 M-1s-1 
E) Tetrazine 56 with alkyne 53 
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Figure 2.12. Reaction rate between IsoP-tetrazine 56(25 uM) and alkyne 53(250 uM, 300 uM, 350 uM, 400 
uM, 450 uM). 
Second order rate constant k2= 40.9 ± 13.8 M-1s-1 
2.4.5 Computational detail 
All calculations were performed using the Gaussian 03 program.211 Initial geometry optimizations 
were carried out at the AM1212 semiempirical level. DFT calculations were carried out with use of the 
B3LYP213,214 with the standard 6-31G** basis set. The stationary points were characterized by frequency 
calculations to verify that TSs had one and only one imaginary frequency. 
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3 CONCLUSIONS 
In summary, as the very first group who found a series of SecA inhibitors that showed novel 
antimicrobial mechanism, we herein designed and synthesized a series of analogues based on the 
structures of two lead inhibitors identified through virtual screening and one lead identified from random 
screening. The best inhibitors showed in vivo IC50 against bacteria from low μM to high nM range. These 
compounds are the first in its class and should be very useful as research tools in studying bacterial 
protein transport. The new inhibitory structural features identified should also be very useful for further 
structural optimization in search of even more potent inhibitors as potential antimicrobial agents with 
novel mechanisms of action. 
Postsynthetic modification provides an important way for DNA modifications. In the present 
research, Neo-TTP was successfully synthesized and incorporated into DNA, which enriched the toolbox 
of DNA postsynthetic functionalization.  Further on the way of finding novel ways for rapid and site-
specific post-synthesis modification of DNA without the issue of regioisomers, we described a new 
inverse electron-demand Diels-Alder reaction involving BCN-tetrazine pair with tunable reaction rates. 
Such reaction with the wide range of reaction rates (over 64-fold difference) that can be achieved suggests 
possibilities of mutiplexing click labeling. This work paves the way to utilize BCN-tetrazine conjugation 
reactions for not only DNA but also other labeling work. 
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Appendix A. 1H and 13C Spectra of compounds in chapter 1 
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